{"ticker": {"uuid": "c1c50c89-31ce-4299-b83b-1107b066ba4d", "symbol": "BNTX", "name": "BioNTech SE", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/moderna-climbs-5-nasdaq-100-154854096.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/moderna-climbs-5-nasdaq-100-154854096.html", "source_link_is_lookup": false, "source_name": "24/7 Wall St.", "published_at": "2026-10-09T15:48:54+00:00", "published_display": "09 Oct 2026 15:48", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Large positive market reaction"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.029948, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 66.5, "age_days": 1.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech SE (BNTX) Stock Price, News, Quote & History", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE44WWdPd1J3d2lqbnFNcndSVkxIWUJiNXVDdWhhVEVtYzhCbU83NU8tWlhfd3JualBnSE92NkFZTHlrTHkwQ3ZiMG5tRGx4STRRSVE?oc=5", "source_link": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE44WWdPd1J3d2lqbnFNcndSVkxIWUJiNXVDdWhhVEVtYzhCbU83NU8tWlhfd3JualBnSE92NkFZTHlrTHkwQ3ZiMG5tRGx4STRRSVE?oc=5", "source_link_is_lookup": false, "source_name": "Yahoo! Finance Canada", "published_at": "2026-10-09T11:05:36+00:00", "published_display": "09 Oct 2026 11:05", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.038228, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 62.2, "age_days": 1.4, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": [], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100?", "summary": "BioNTech is transitioning from a COVID-19 vaccine producer to a major oncology company, with a robust late-stage cancer pipeline that includes over 25 phase 2 and phase 3 trials. Its lead candidate, pumitamig, is being tested across multiple solid tumor types, and the company plans to have 15 phase 3 trials by 2026. Despite a recent revenue drop, BioNTech's strong balance sheet and diversified pipeline suggest significant upside potential, making its current stock price under $100 an attractive entry point for investors.", "url": "https://www.fool.com/investing/2026/10/08/biontech-has-more-cancer-drugs-in-late-stage-trial", "source_link": "https://www.fool.com/investing/2026/10/08/biontech-has-more-cancer-drugs-in-late-stage-trial", "source_link_is_lookup": false, "source_name": "The Motley Fool", "published_at": "2026-10-08T17:34:42", "published_display": "08 Oct 2026 17:34", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Operating deterioration", "Positive valuation view"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.114811, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 74.7, "age_days": 2.1, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Is BioNTech (BNTX) Undervalued On Pipeline Promise Despite Revenue Of \u20ac2,650.0 Million And Losses?", "summary": "", "url": "https://news.google.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?oc=5", "source_link": "https://news.google.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?oc=5", "source_link_is_lookup": false, "source_name": "Simply Wall Street", "published_at": "2026-10-08T04:03:31+00:00", "published_display": "08 Oct 2026 04:03", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Positive valuation view"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.067521, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 69.1, "age_days": 2.7, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Is BioNTech (NasdaqGS:BNTX) Overvalued As Sales Face A Reset?", "summary": "BioNTech has seen its share price slide over recent years while the business reshapes itself beyond the COVID-19 vaccine boom, which naturally puts the focus back on what investors are paying for its current and potential sales base. With market sentiment shifting around the restructuring of its manufacturing footprint and the oncology pipeline, the live question is how well the present US$95.73 price lines up with the revenue the company is generating and expects to generate. The stock has fallen 60.3% over 5 years, which raises the issue of whether the market is now pricing BioNTech more on ", "url": "https://finance.yahoo.com/markets/stocks/articles/biontech-nasdaqgs-bntx-overvalued-sales-211241777.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/biontech-nasdaqgs-bntx-overvalued-sales-211241777.html", "source_link_is_lookup": false, "source_name": "Simply Wall St.", "published_at": "2026-10-07T21:12:41+00:00", "published_display": "07 Oct 2026 21:12", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 45, "tone_signals": ["Negative valuation view", "Negative market reaction"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.022805, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 36.0, "age_days": 3.0, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Biotech", "Earnings", "Oncology", "Restructuring", "Share Price", "Valuation"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Under a prearranged trading plan, BioNTech (BNTX) CEO Ugur Sahin sells 24,000 shares.", "summary": "BioNTech CEO Ugur Sahin sold 24,000 ordinary shares at $95.8597 per share on October 7, 2026, through a pre-established Rule 10b5-1 trading plan. After the sale, his direct holdings amounted to 63,209 ordinary shares. Additionally, 39,218,111 ordinary shares are held indirectly through Medine GmbH, a company wholly owned by Sahin.", "url": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-160388166f17.html", "source_link": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-160388166f17.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-10-07T21:28:47", "published_display": "07 Oct 2026 21:28", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 40, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.050869, "evidence_share": 15.4, "evidence_share_display": "15.4", "freshness_pct": 36.1, "age_days": 2.9, "influence_label": "Medium", "evidence_strength": 43, "duplicate_count": 1, "topics": ["Life Sciences", "Financial Markets", "Finance", "Earnings"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech SE : Gets a Buy rating from Berenberg", "summary": "Berenberg has reiterated its \"Buy\" rating for BioNTech SE, with analyst Luisa Hector maintaining a positive outlook on the stock. The target price for BioNTech SE shares remains set at USD 140. This news was published on October 7, 2026.", "url": "https://www.marketscreener.com/news/biontech-se-gets-a-buy-rating-from-berenberg-ce785dd9d089f322", "source_link": "https://www.marketscreener.com/news/biontech-se-gets-a-buy-rating-from-berenberg-ce785dd9d089f322", "source_link_is_lookup": false, "source_name": "marketscreener.com", "published_at": "2026-10-07T08:24:50", "published_display": "07 Oct 2026 08:24", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "positive", "sentiment_pct": 69, "tone_signals": ["Buy Rating"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.087554, "evidence_share": 26.5, "evidence_share_display": "26.5", "freshness_pct": 44.7, "age_days": 3.5, "influence_label": "Medium", "evidence_strength": 54, "duplicate_count": 1, "topics": ["Life Sciences", "Financial Markets"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "Biontech Insider Sold Shares Worth $9,033,642, According to a Recent SEC Filing", "summary": "A recent SEC filing indicates that an insider at BioNTech (BNTX) sold shares valued at $9,033,642. This transaction is part of a series of insider share sales for the company, with previous sales noted on September 11th and September 8th. BioNTech is a German biotechnology company specializing in patient-specific immunotherapies for cancer and other serious diseases.", "url": "https://www.marketscreener.com/news/biontech-insider-sold-shares-worth-9-033-642-according-to-a-recent-sec-filing-ce785dd9dc81f322", "source_link": "https://www.marketscreener.com/news/biontech-insider-sold-shares-worth-9-033-642-according-to-a-recent-sec-filing-ce785dd9dc81f322", "source_link_is_lookup": false, "source_name": "www.marketscreener.com", "published_at": "2026-10-06T21:01:04", "published_display": "06 Oct 2026 21:01", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 40, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.035731, "evidence_share": 10.8, "evidence_share_display": "10.8", "freshness_pct": 25.4, "age_days": 4.0, "influence_label": "Medium", "evidence_strength": 40, "duplicate_count": 1, "topics": ["Life Sciences", "Earnings"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/moderna-surges-8-full-melanoma-184702779.html", "source_link": "https://finance.yahoo.com/healthcare/articles/moderna-surges-8-full-melanoma-184702779.html", "source_link_is_lookup": false, "source_name": "24/7 Wall St.", "published_at": "2026-10-05T18:47:02+00:00", "published_display": "05 Oct 2026 18:47", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Positive market reaction", "Large positive market reaction"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.008188, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 17.4, "age_days": 5.1, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech stock draws Moderate Buy consensus at USD 126 target", "summary": "BioNTech stock received a \"Moderate Buy\" consensus from 19 brokerages with an average target price of USD 126, despite a challenging second quarter that saw significant GAAP net losses. While analysts anticipate a higher valuation, the company's financial performance highlights its dependence on its oncology pipeline as COVID-19 vaccine revenue decreases. The stock's current trading price of USD 97.10 is 29.7% below the analyst target and USD 26.90 below its 52-week high of USD 124.00.", "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/biontech-stock-draws-moderate-buy-consensus-at-usd-126-target/70234906", "source_link": "https://www.ad-hoc-news.de/boerse/news/corporate-news/biontech-stock-draws-moderate-buy-consensus-at-usd-126-target/70234906", "source_link_is_lookup": false, "source_name": "AD HOC NEWS", "published_at": "2026-10-05T18:26:00", "published_display": "05 Oct 2026 18:26", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Negative financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.060761, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 49.5, "age_days": 5.1, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech (BNTX) CEO Ugur Sahin sells 72,000 and 21,000 shares under a June 3 trading plan.", "summary": "BioNTech CEO Ugur Sahin reported direct sales of 72,000 ordinary shares on October 5, 2026, at $97.2312 per share and 21,000 ordinary shares on October 6, 2026, at $96.8093 per share. These transactions were executed under a Rule 10b5-1 trading plan established on June 3, 2026. Sahin's indirect holdings through Medine GmbH, where he is the sole shareholder, amount to 39,218,111 shares.", "url": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-14b0b2b132d1.html", "source_link": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-14b0b2b132d1.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-10-05T09:28:47", "published_display": "05 Oct 2026 09:28", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 42, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.017498, "evidence_share": 5.3, "evidence_share_display": "5.3", "freshness_pct": 15.2, "age_days": 5.4, "influence_label": "Low", "evidence_strength": 34, "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech to close three German sites. BioNTech stock costs EUR 86.10 in weekend trading", "summary": "BioNTech announced it would close three German sites after failing to sell them, marking a shift away from pandemic-era manufacturing. The company's stock was trading at EUR 86.10 in weekend trading, matching its previous closing price. This news follows a recent release of updated trial data for their cancer treatment, gotistobart, showing promising results.", "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/biontech-to-close-three-german-sites-biontech-stock-costs-eur-86-10-in/70220956", "source_link": "https://www.ad-hoc-news.de/boerse/news/corporate-news/biontech-to-close-three-german-sites-biontech-stock-costs-eur-86-10-in/70220956", "source_link_is_lookup": false, "source_name": "AD HOC NEWS", "published_at": "2026-10-03T13:00:00", "published_display": "03 Oct 2026 13:00", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.005731, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 8.0, "age_days": 7.3, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences", "Manufacturing"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech SE (BNTX) options chain \u2013 Yahoo Finance", "summary": "This page from Yahoo Finance provides information on BioNTech SE (BNTX), including its stock summary, news, chart, statistics, historical data, profile, financials, analysis, options, and holders. It notes the current stock price and highlights that there are no options listed for the company at this time.", "url": "https://sg.finance.yahoo.com/quote/BNTX/options?date=1826582400&straddle=true", "source_link": "https://sg.finance.yahoo.com/quote/BNTX/options?date=1826582400&straddle=true", "source_link_is_lookup": false, "source_name": "Market source", "published_at": "2026-10-03T05:01:04", "published_display": "03 Oct 2026 05:01", "source_kind": "aggregator", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.00383, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 7.1, "age_days": 7.6, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech (BNTX) CEO sells 17,000 shares twice under a preset trading plan", "summary": "BioNTech CEO Ugur Sahin sold 17,000 ordinary shares on October 1, 2026, at $97.4556 per share, and another 17,000 shares on October 2, 2026, at $96.7249 per share. These sales were executed under a pre-established Rule 10b5-1 trading plan. Sahin also holds a significant indirect stake of 39,218,111 shares through Medine GmbH, where he is the sole shareholder, with a portion of these held in a trust arrangement.", "url": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-b0c5f8cc0bb7.html", "source_link": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-b0c5f8cc0bb7.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-10-02T20:34:37", "published_display": "02 Oct 2026 20:34", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 40, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.008876, "evidence_share": 2.7, "evidence_share_display": "2.7", "freshness_pct": 6.3, "age_days": 8.0, "influence_label": "Low", "evidence_strength": 35, "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech SE (BNTX) Stock Price, News, Quote & History", "summary": "This Yahoo Finance page provides comprehensive financial information for BioNTech SE (22UA.F), including its current stock price, historical data, and key statistics. It details the company's overview as a biotechnology firm involved in developing immunotherapies, particularly its SARS-CoV-2 vaccine and various oncology drugs in clinical trials. The article also presents performance metrics, earnings trends, and valuation measures for BioNTech SE.", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE44WWdPd1J3d2lqbnFNcndSVkxIWUJiNXVDdWhhVEVtYzhCbU83NU8tWlhfd3JualBnSE92NkFZTHlrTHkwQ3ZiMG5tRGx4STRRSVE?oc=5", "source_link": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE44WWdPd1J3d2lqbnFNcndSVkxIWUJiNXVDdWhhVEVtYzhCbU83NU8tWlhfd3JualBnSE92NkFZTHlrTHkwQ3ZiMG5tRGx4STRRSVE?oc=5", "source_link_is_lookup": false, "source_name": "Yahoo! Finance Canada", "published_at": "2026-10-01T16:05:42+00:00", "published_display": "01 Oct 2026 16:05", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.023762, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 28.1, "age_days": 9.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Moderna Climbs 3% Despite Citigroup\u2019s Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/moderna-climbs-3-despite-citigroup-150011294.html", "source_link": "https://finance.yahoo.com/healthcare/articles/moderna-climbs-3-despite-citigroup-150011294.html", "source_link_is_lookup": false, "source_name": "24/7 Wall St.", "published_at": "2026-10-01T15:00:11+00:00", "published_display": "01 Oct 2026 15:00", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Analyst downgrade"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001938, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 4.1, "age_days": 9.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Under a June 3 trading plan, BioNTech (BNTX) CEO Ugur Sahin sells 34,000 and 32,000 shares.", "summary": "BioNTech CEO Ugur Sahin reported direct sales of 34,000 ordinary shares at $98.2591 and 32,000 ordinary shares at $98.1203 on September 29 and September 30, 2026, respectively. These transactions were executed under a Rule 10b5-1 trading plan established on June 3, 2026. Sahin also indirectly beneficially owns 39,218,111 ordinary shares through Medine GmbH, which holds voting power over 106,721 shares in a trust for an individual.", "url": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-3d6c943e4876.html", "source_link": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-3d6c943e4876.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-09-30T20:27:06", "published_display": "30 Sep 2026 20:27", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 42, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.003624, "evidence_share": 1.1, "evidence_share_display": "1.1", "freshness_pct": 3.1, "age_days": 10.0, "influence_label": "Low", "evidence_strength": 31, "duplicate_count": 1, "topics": ["Earnings", "Finance", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech Steps Deeper Into Lung Cancer With New Dareon-Rosetta35 Trial", "summary": "BioNTech announced the Dareon-Rosetta35 trial, a Phase Ib/II study evaluating new cancer drugs, obrixtamig and pumitamig, for advanced small cell lung cancer. This trial, a partnership with Boehringer Ingelheim, aims to assess drug tolerability and tumor response, marking BioNTech's expansion into solid tumors beyond vaccines. The study is interventional and open-label, focusing on safety and early signs of efficacy, and could provide a new revenue stream for BNTX if successful.", "url": "https://www.tipranks.com/news/company-announcements/biontech-steps-deeper-into-lung-cancer-with-new-dareon-rosetta35-trial", "source_link": "https://www.tipranks.com/news/company-announcements/biontech-steps-deeper-into-lung-cancer-with-new-dareon-rosetta35-trial", "source_link_is_lookup": false, "source_name": "TipRanks", "published_at": "2026-09-30T16:27:06", "published_display": "30 Sep 2026 16:27", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.027033, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 24.5, "age_days": 10.1, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?", "summary": "Moderna (MRNA) and BioNTech (BNTX), both prominent in mRNA technology, are transitioning from COVID-19 vaccine reliance to developing new therapies. Moderna appears to be further along in this diversification, with approved respiratory vaccines and positive late-stage oncology results. BioNTech, while having a broader oncology pipeline, faces greater challenges with revenue replacement as COVID-19 vaccine demand normalizes and has experienced recent clinical setbacks.", "url": "https://finance.yahoo.com/healthcare/articles/moderna-vs-biontech-mrna-stock-150100907.html", "source_link": "https://finance.yahoo.com/healthcare/articles/moderna-vs-biontech-mrna-stock-150100907.html", "source_link_is_lookup": false, "source_name": "Zacks", "published_at": "2026-09-30T15:01:00+00:00", "published_display": "30 Sep 2026 15:01", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001866, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 2.9, "age_days": 10.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 3, "topics": ["Biotech", "Covid 19", "Earnings", "Financial Markets", "Life Sciences", "Oncology"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech stock trades at EUR 86.05 after a revenue miss", "summary": "BioNTech's stock is trading at EUR 86.05 following a significant revenue miss in Q2 2026, with revenue dropping by 59.50% to EUR 105.6 million. The company also reported a GAAP net loss and reduced its full-year revenue guidance, as its transition from COVID vaccine revenue to oncology growth faces challenges, including the termination of a Phase 2 colorectal cancer trial. Despite these setbacks, Berenberg raised its price target for BioNTech to USD 140.00 with a Buy rating.", "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/biontech-stock-trades-at-eur-86-05-after-a-revenue-miss/70205151", "source_link": "https://www.ad-hoc-news.de/boerse/news/corporate-news/biontech-stock-trades-at-eur-86-05-after-a-revenue-miss/70205151", "source_link_is_lookup": false, "source_name": "AD HOC NEWS", "published_at": "2026-09-30T14:32:28", "published_display": "30 Sep 2026 14:32", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 21, "tone_signals": ["Missed expectations", "Guidance cut"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.029271, "evidence_share": 8.9, "evidence_share_display": "8.9", "freshness_pct": 9.4, "age_days": 10.2, "influence_label": "High", "evidence_strength": 58, "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech (NasdaqGS:BNTX) Stock Forecast & Analyst Predictions", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQRXJseEVnMTg5RXZ5M0p5Zml4QlZDdG9HdjdTeXRUWWpGa3ZabW5QNk85bGlrN3RSQ29uWXJrcFY5cVV3eWEwZ3BDT0xrbFJ2UjFaa1l1bE54cTFTSG5TMzl1dy1zdmxKVWNyQ3FPMm9FQlJpV3RFSjNsWXdSZGVmUk1YM05VVlFPbFZv?oc=5", "source_link": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQRXJseEVnMTg5RXZ5M0p5Zml4QlZDdG9HdjdTeXRUWWpGa3ZabW5QNk85bGlrN3RSQ29uWXJrcFY5cVV3eWEwZ3BDT0xrbFJ2UjFaa1l1bE54cTFTSG5TMzl1dy1zdmxKVWNyQ3FPMm9FQlJpV3RFSjNsWXdSZGVmUk1YM05VVlFPbFZv?oc=5", "source_link_is_lookup": false, "source_name": "Simply Wall Street", "published_at": "2026-09-30T07:00:00+00:00", "published_display": "30 Sep 2026 07:00", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.039973, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 35.2, "age_days": 10.5, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": false}, {"title": "Pfizer, BioNTech, Moderna dealt blow in effort to dismiss mRNA patent lawsuits", "summary": "[Intellectual Property mind map diagram with patent, trademark, copyright, license, infringement, trade secret on notepad] Ployker/iStock via Getty Images * A Delaware federal judge on Monday rejected requests from Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), BioNTech (BNTX [https://seekingalpha.com/symbol/BNTX]), and Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) to dismiss lawsuits filed against them by Bayer's (BAYZF [https://seekingalpha.com/symbol/BAYZF])(BAYRY [https://seekingalpha.com/symbol/BAYRY]) Monsanto unit regarding the drugmakers' use of a patent related to mRNA te", "url": "https://seekingalpha.com/news/4647773-pfizer-biontech-moderna-dealt-blow-effort-dismiss-mrna-patent-lawsuits?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4647773-pfizer-biontech-moderna-dealt-blow-effort-dismiss-mrna-patent-lawsuits?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-09-28T20:38:01+00:00", "published_display": "28 Sep 2026 20:38", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.025486, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 30.6, "age_days": 12.0, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Biotech", "M A", "Patent Dispute", "Vaccines"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "A trading plan covers BioNTech (BNTX) CEO Ugur Sahin's sales of 27,000 and 34,000 shares.", "summary": "BioNTech CEO Ugur Sahin reported direct sales of 27,000 ordinary shares on September 25, 2026, and 34,000 ordinary shares on September 28, 2026, both executed under a Rule 10b5-1 trading plan established in June 2026. The sales were priced at $98.6882 and $98.4682 per share, respectively. Sahin retains significant indirect holdings through Medine GmbH.", "url": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-31a9faabda7c.html", "source_link": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-31a9faabda7c.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-09-28T21:23:36", "published_display": "28 Sep 2026 21:23", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001144, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 1.6, "age_days": 11.9, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech to Close 3 German Sites After Unsuccessful Sale Efforts", "summary": "BioNTech announced it will close three German sites after failing to sell them. The company, known for its COVID-19 vaccine, has been restructuring and adjusting its operations. This move reflects ongoing efforts to optimize its asset portfolio.", "url": "https://www.marketscreener.com/news/biontech-to-close-3-german-sites-after-unsuccessful-sale-efforts-ce785adcd18df22c", "source_link": "https://www.marketscreener.com/news/biontech-to-close-3-german-sites-after-unsuccessful-sale-efforts-ce785adcd18df22c", "source_link_is_lookup": false, "source_name": "marketscreener.com", "published_at": "2026-09-28T16:23:36", "published_display": "28 Sep 2026 16:23", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001064, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 1.5, "age_days": 12.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences", "Mergers And Acquisitions"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech to close 3 German plants", "summary": "BioNTech announced its decision to close three manufacturing plants in Germany. This move is part of the company's strategic adjustments. Further details regarding the reasons for closure and the impact are expected.", "url": "https://breakingthenews.net/Article/BioNTech-to-close-3-German-plants/67188203", "source_link": "https://breakingthenews.net/Article/BioNTech-to-close-3-German-plants/67188203", "source_link_is_lookup": false, "source_name": "Breakingthenews.net", "published_at": "2026-09-28T12:23:36", "published_display": "28 Sep 2026 12:23", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Negative financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001004, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 1.4, "age_days": 12.3, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Life Sciences", "Manufacturing"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech SE stock carries a USD 127.44 consensus target after Q2 miss", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNenJxaEV3bjNMZXdLSzRZaTBIVFJydF9OWFNrWVM0TjNYMi14M1VLTjFiTldzdW1PdnRfVkw0YkdaQVJ6RkRzWmJtY2hhUUZjcUI0ajF3NlJabU5yRDhRNWFVelMtVVRKQWZXYmVpTTJnN09RbkRGZnRLOHl5S0NTeDJwVFZnTlRmOW9mUDRxVnNZVEZIVDR0N3BVR095c3pKMUdkNUVxUkVlSW1LVGVTMGdlMmEzS01CeVgzUW9GX0V0YkdtdDBtc2lrcW8?oc=5", "source_link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNenJxaEV3bjNMZXdLSzRZaTBIVFJydF9OWFNrWVM0TjNYMi14M1VLTjFiTldzdW1PdnRfVkw0YkdaQVJ6RkRzWmJtY2hhUUZjcUI0ajF3NlJabU5yRDhRNWFVelMtVVRKQWZXYmVpTTJnN09RbkRGZnRLOHl5S0NTeDJwVFZnTlRmOW9mUDRxVnNZVEZIVDR0N3BVR095c3pKMUdkNUVxUkVlSW1LVGVTMGdlMmEzS01CeVgzUW9GX0V0YkdtdDBtc2lrcW8?oc=5", "source_link_is_lookup": false, "source_name": "AD HOC NEWS", "published_at": "2026-09-28T11:06:11+00:00", "published_display": "28 Sep 2026 11:06", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 43, "tone_signals": ["Negative financial language"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.005916, "evidence_share": 1.8, "evidence_share_display": "1.8", "freshness_pct": 5.7, "age_days": 12.4, "influence_label": "Low", "evidence_strength": 30, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": true}, {"title": "Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside?", "summary": "This article compares Moderna (MRNA) and BioNTech (BNTX) as investments in the mRNA cancer stock sector. It evaluates Moderna's clinical lead in cancer results against BioNTech's financial flexibility and broader oncology pipeline. The piece aims to determine which company offers a more attractive long-term setup for investors.", "url": "https://www.fool.com/investing/2026/09/28/moderna-vs-biontech-which-mrna-cancer-stock-has-mo", "source_link": "https://www.fool.com/investing/2026/09/28/moderna-vs-biontech-which-mrna-cancer-stock-has-mo", "source_link_is_lookup": false, "source_name": "The Motley Fool", "published_at": "2026-09-28T10:42:00", "published_display": "28 Sep 2026 10:42", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.028299, "evidence_share": 8.6, "evidence_share_display": "8.6", "freshness_pct": 18.0, "age_days": 12.4, "influence_label": "Low", "evidence_strength": 33, "duplicate_count": 2, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "How New Lung Cancer Data And Updated COVID Shot At BioNTech (BNTX) Has Changed Its Investment Story", "summary": "BioNTech's investment narrative is shifting due to new lung cancer data and an updated COVID-19 vaccine. The investigational CTLA\u20114 antibody gotistobart nearly doubled median overall survival in a Phase 3 lung cancer trial, boosting BioNTech's oncology pipeline. While COVID-19 vaccine revenue provides short-term cash flow, the company is heavily investing in oncology to secure long-term profitability, despite risks of prolonged losses and delayed approvals.", "url": "https://finance.yahoo.com/healthcare/articles/lung-cancer-data-updated-covid-011057743.html", "source_link": "https://finance.yahoo.com/healthcare/articles/lung-cancer-data-updated-covid-011057743.html", "source_link_is_lookup": false, "source_name": "Simply Wall St.", "published_at": "2026-09-27T01:10:57+00:00", "published_display": "27 Sep 2026 01:10", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Negative financial language"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.024858, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 25.5, "age_days": 13.8, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 3, "topics": ["Biotech", "Earnings", "Financial Markets", "Healthcare", "Life Sciences", "Oncology"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech SE (22UA.F) Stock Price, News, Quote & History", "summary": "This Yahoo Finance page provides comprehensive financial information for BioNTech SE (22UA.F), including its current stock price, historical data, and key statistics. It details the company's overview as a biotechnology firm involved in developing immunotherapies, particularly its SARS-CoV-2 vaccine and various oncology drugs in clinical trials. The article also presents performance metrics, earnings trends, and valuation measures for BioNTech SE.", "url": "https://ca.finance.yahoo.com/quote/22UA.F", "source_link": "https://ca.finance.yahoo.com/quote/22UA.F", "source_link_is_lookup": false, "source_name": "Yahoo! Finance Canada", "published_at": "2026-09-25T10:53:55", "published_display": "25 Sep 2026 10:53", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.010037, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 11.9, "age_days": 15.4, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Form 4 BioNTech SE For: 25 September By Investing.com", "summary": "This article announces the filing of a Form 4 for BioNTech SE on September 25. It is a brief financial news update indicating a regulatory filing concerning the company. The article also lists BioNTech's stock performance for the day.", "url": "https://ca.investing.com/news/stock-market-news/form-4-biontech-se-for-25-september-93CH-4853124", "source_link": "https://ca.investing.com/news/stock-market-news/form-4-biontech-se-for-25-september-93CH-4853124", "source_link_is_lookup": false, "source_name": "Investing.com Canada", "published_at": "2026-09-25T08:53:56", "published_display": "25 Sep 2026 08:53", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.037527, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 21.6, "age_days": 15.5, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?", "summary": "Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026\u20132027 COVID-19 vaccine formula, COMIRNATY XFG. The updated formula targets the XFG variant and is authorized for adults aged 65 and older, as well as individuals aged 5 to 64 with high-risk underlying conditions. Based on clinical, real-world, and manufacturing data demonstrating strong immune responses against circulating strains, the approval aligns with FDA strain guidance for fall 2026. You May Also Want to Look At: Pfizer (", "url": "https://finance.yahoo.com/healthcare/articles/could-vaccine-formula-xfg-pfizer-202715476.html", "source_link": "https://finance.yahoo.com/healthcare/articles/could-vaccine-formula-xfg-pfizer-202715476.html", "source_link_is_lookup": false, "source_name": "Insider Monkey", "published_at": "2026-09-24T20:27:15+00:00", "published_display": "24 Sep 2026 20:27", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 52, "tone_signals": ["Contract or approval won"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.009978, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 10.9, "age_days": 16.0, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 3, "topics": ["Balance Sheet", "Covid 19 Vaccine", "Fda Approval", "Pharma"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech (BNTX) CEO Ugur Sahin sold shares on two days under a trading plan set in June.", "summary": "BioNTech CEO Ugur Sahin sold 69,000 ordinary shares of BNTX on September 23 and 24, 2026, under a Rule 10b5-1 trading plan established on June 3, 2026. The sales totaled approximately $6.84 million, with shares sold at prices of $99.4027 and $98.9913, respectively. Sahin still indirectly holds over 39 million shares through Medine GmbH, where he is the sole shareholder.", "url": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-4d1305766bd5.html", "source_link": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-4d1305766bd5.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-09-24T20:53:56", "published_display": "24 Sep 2026 20:53", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 40, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000557, "evidence_share": 0.2, "evidence_share_display": "0.2", "freshness_pct": 0.4, "age_days": 16.0, "influence_label": "Low", "evidence_strength": 34, "duplicate_count": 1, "topics": ["Earnings", "Finance", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BNTX Stock Price and Chart \u2014 NASDAQ:BNTX", "summary": "This article provides an overview of BioNTech SE (NASDAQ: BNTX) stock, including its price performance, key facts, and financial statistics. Recent developments include potential job cuts and site closures, ongoing patent litigation with Bayer CropScience, and a revised price target from Citi. The company continues to be active in mRNA technology beyond COVID-19, with a focus on oncology and other therapies.", "url": "https://www.tradingview.com/symbols/NASDAQ-BNTX", "source_link": "https://www.tradingview.com/symbols/NASDAQ-BNTX", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-09-24T13:00:44", "published_display": "24 Sep 2026 13:00", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Operational disruption"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000194, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.4, "age_days": 16.3, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Canaccord Genuity Reaffirms Their Buy Rating on BioNTech SE (BNTX)", "summary": "Canaccord Genuity analyst John Newman maintained a Buy rating on BioNTech SE (BNTX) with a price target of $136.00. This rating aligns with Morgan Stanley's Buy rating, though BMO Capital has a Hold rating on the stock. BioNTech SE reported a quarterly revenue of $105.6 million and a GAAP net loss of $820.8 million for the quarter ending June 30.", "url": "https://www.theglobeandmail.com/investing/markets/stocks/BNTX-Q/pressreleases/4774321/canaccord-genuity-reaffirms-their-buy-rating-on-biontech-se-bntx", "source_link": "https://www.theglobeandmail.com/investing/markets/stocks/BNTX-Q/pressreleases/4774321/canaccord-genuity-reaffirms-their-buy-rating-on-biontech-se-bntx", "source_link_is_lookup": false, "source_name": "The Globe and Mail", "published_at": "2026-09-24T12:53:56", "published_display": "24 Sep 2026 12:53", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "positive", "sentiment_pct": 71, "tone_signals": ["Buy Rating"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.005266, "evidence_share": 1.6, "evidence_share_display": "1.6", "freshness_pct": 2.3, "age_days": 16.3, "influence_label": "Medium", "evidence_strength": 45, "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech stock rises 2.0 percent after the close", "summary": "BioNTech stock rose 2.0 percent after the close on September 22, 2026, reaching USD 100.42 in Tuesday morning trading on the Nasdaq. This increase followed a prior Nasdaq close of USD 97.71 on September 21, and the company had gained 5 percent year-to-date. The outlook also noted that BMO had recently lowered its 12-month target for BioNTech shares from USD 128 to USD 105.", "url": "https://www.ad-hoc-news.de/boerse/news/nebenwerte/biontech-stock-rises-2-0-percent-after-the-close/70159583", "source_link": "https://www.ad-hoc-news.de/boerse/news/nebenwerte/biontech-stock-rises-2-0-percent-after-the-close/70159583", "source_link_is_lookup": false, "source_name": "AD HOC NEWS", "published_at": "2026-09-22T22:30:00", "published_display": "22 Sep 2026 22:30", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.030742, "evidence_share": 9.3, "evidence_share_display": "9.3", "freshness_pct": 17.0, "age_days": 17.9, "influence_label": "Medium", "evidence_strength": 36, "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech (NASDAQ: BNTX) CEO sells 79K shares, still holds 39.2M", "summary": "BioNTech CEO Ugur Sahin sold 79,000 Ordinary Shares of BNTX on September 21-22, 2026, through a Rule 10b5-1 trading plan. Despite these sales, Sahin retains a significant indirect stake of 39,218,111 Ordinary Shares held via Medine GmbH, for which he is the sole shareholder. The transactions were executed at prices of $100.7182 and $97.8097 per share.", "url": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-bce53a94a80e.html", "source_link": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-bce53a94a80e.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-09-22T20:54:37", "published_display": "22 Sep 2026 20:54", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "negative", "sentiment_pct": 40, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000279, "evidence_share": 0.1, "evidence_share_display": "<0.1", "freshness_pct": 0.2, "age_days": 18.0, "influence_label": "Low", "evidence_strength": 34, "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech price tries to regain footing - Forecast today - 23-09-2026", "summary": "BioNTech SE (BNTX) showed an advance in recent intraday trading, finding support at its 50-day Simple Moving Average and exhibiting fresh bullish signals from momentum indicators in oversold territory. The stock is maintaining a short-term uptrend, following an ascending trendline. The outlook remains bullish as long as support at $95.30 holds, with an expected target of $105.50 for its first resistance level.", "url": "https://www.economies.com/stocks/united-states-analysis/biontech-price-tries-to-regain-footing---forecast-today---23-09-2026-130438", "source_link": "https://www.economies.com/stocks/united-states-analysis/biontech-price-tries-to-regain-footing---forecast-today---23-09-2026-130438", "source_link_is_lookup": false, "source_name": "Economies.com", "published_at": "2026-09-22T12:32:00", "published_display": "22 Sep 2026 12:32", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Positive financial language"], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.023959, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 16.3, "age_days": 18.3, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?", "summary": "BMO Capital Markets downgraded BioNTech (BNTX) from \"outperform\" to \"market perform\" and lowered its price target due to waning COVID-19 vaccine demand and a setback in its colorectal cancer vaccine trial. Despite these challenges and a revised revenue forecast, the article argues that BioNTech's extensive oncology pipeline, with over 25 Phase 2 and Phase 3 clinical studies, is being underestimated by Wall Street. The company also holds significant cash reserves, suggesting that investors can acquire a robust pipeline at a perceived value.", "url": "https://www.fool.com/investing/2026/09/22/biontech-stock-recently-got-downgraded-but-is-wall", "source_link": "https://www.fool.com/investing/2026/09/22/biontech-stock-recently-got-downgraded-but-is-wall", "source_link_is_lookup": false, "source_name": "The Motley Fool", "published_at": "2026-09-22T09:54:37", "published_display": "22 Sep 2026 09:54", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 46, "tone_signals": ["Analyst downgrade"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001825, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 1.4, "age_days": 18.4, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Biotech", "Cancer", "Clinical Trials", "Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech SE (BNTX) Stock Analysis: Navigating a 23% Potential Upside Amidst Challenging Financials", "summary": "BioNTech SE (BNTX), a German biotechnology firm known for its mRNA vaccine, presents a potential 23% upside despite current financial challenges including a negative P/E ratio and revenue growth. The company is strategically diversifying its pipeline into oncology and other infectious diseases. While financial metrics suggest caution, analyst ratings remain optimistic, highlighting a balance between innovative potential and financial health for investors.", "url": "https://www.directorstalkinterviews.com/biontech-se-bntx-stock-analysis-navigating-a-23-potential-upside-amidst-challenging-financials/4121263202", "source_link": "https://www.directorstalkinterviews.com/biontech-se-bntx-stock-analysis-navigating-a-23-potential-upside-amidst-challenging-financials/4121263202", "source_link_is_lookup": false, "source_name": "DirectorsTalk Interviews", "published_at": "2026-09-22T05:54:37", "published_display": "22 Sep 2026 05:54", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "positive", "sentiment_pct": 61, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.015193, "evidence_share": 4.6, "evidence_share_display": "4.6", "freshness_pct": 7.6, "age_days": 18.6, "influence_label": "Medium", "evidence_strength": 38, "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher", "summary": "Quick Read Moderna surged 9% to $168 after its Phase 3 melanoma vaccine study earned the ESMO congress's highest-profile Presidential Symposium slot on October 24. Merck gained just 1% and BioNTech 2%, signaling the market views this as a Moderna-specific re-rating, not a broad mRNA oncology validation. No new efficacy data was released Monday; the Presidential Symposium slot itself is the signal, as organizers reserve it for practice-changing datasets. Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Merck didn't make the cut. Ente", "url": "https://finance.yahoo.com/healthcare/articles/moderna-surges-9-phase-3-154555747.html", "source_link": "https://finance.yahoo.com/healthcare/articles/moderna-surges-9-phase-3-154555747.html", "source_link_is_lookup": false, "source_name": "24/7 Wall St.", "published_at": "2026-09-21T15:45:55+00:00", "published_display": "21 Sep 2026 15:45", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Positive market reaction", "Large positive market reaction"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 6.1e-05, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.1, "age_days": 19.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Biotech", "Clinical Trials", "Moderna", "Oncology", "Price Target", "Split"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech SE - American Depositary Shares (NQ: BNTX)", "summary": "This article provides a brief overview of BioNTech SE (BNTX) stock performance, showing a price of 100.87 with a 2.87 (+2.93%) increase, as of 4:00 PM EDT, Sep 22, 2026. It lists various sections for investors to find more information, such as detailed quotes, charting, historical prices, news, and research reports. The content primarily focuses on providing a framework for accessing financial data related to BioNTech SE.", "url": "https://markets.chroniclejournal.com/observerreporter/quote/news?Symbol=NQ%3ABNTX&CurrentPage=63", "source_link": "https://markets.chroniclejournal.com/observerreporter/quote/news?Symbol=NQ%3ABNTX&CurrentPage=63", "source_link_is_lookup": false, "source_name": "The Chronicle-Journal", "published_at": "2026-09-19T05:54:37", "published_display": "19 Sep 2026 05:54", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 4e-05, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.1, "age_days": 21.6, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher", "summary": "Quick Read Moderna surged 5% to $152.83, extending a stunning 137% one-month run fueled solely by its Phase 2b melanoma vaccine data showing a 49% reduction in recurrence risk. BioNTech edged up just 1% despite running a rival mRNA cancer vaccine program, signaling markets are backing Moderna's specific asset, not the broader platform. A Phase 3 adjuvant melanoma interim analysis expected in late 2026 is the next swing factor, with Madrid's October oncology congress as the nearest public data window. Read More: Avoid these 13 retirement mistakes before they derail your future (sponsor) Cancer ", "url": "https://finance.yahoo.com/healthcare/articles/moderna-climbs-6-cancer-vaccine-135031898.html", "source_link": "https://finance.yahoo.com/healthcare/articles/moderna-climbs-6-cancer-vaccine-135031898.html", "source_link_is_lookup": false, "source_name": "24/7 Wall St.", "published_at": "2026-09-17T13:50:31+00:00", "published_display": "17 Sep 2026 13:50", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Large positive market reaction", "Positive market reaction"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 1.5e-05, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.0, "age_days": 23.3, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Biotech", "Cancer Vaccine", "Clinical Trials", "Earnings", "Guidance", "Revenue Growth"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Is BioNTech (BNTX) Too Pricey for Its Current Sales Base?", "summary": "BioNTech has been in focus again after fresh clinical trial results, yet the long slide in the share price keeps pulling attention back to a simple question about what investors are paying for its sales. With the stock well below where it traded several years ago, the issue is whether today's valuation rests on a solid revenue base or on expectations that are hard to pin down. Over the past 5 years the share price has fallen 71.5%, which puts the spotlight firmly on whether the current valuation can still be explained by the company's sales profile. News that gotistobart nearly doubled median ", "url": "https://finance.yahoo.com/healthcare/articles/biontech-bntx-too-pricey-current-221344796.html", "source_link": "https://finance.yahoo.com/healthcare/articles/biontech-bntx-too-pricey-current-221344796.html", "source_link_is_lookup": false, "source_name": "Simply Wall St.", "published_at": "2026-09-16T22:13:44+00:00", "published_display": "16 Sep 2026 22:13", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Missed expectations", "Improving financial comparison"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.002845, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 3.6, "age_days": 23.9, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Biotech", "Clinical Trials", "Oncology", "Share Price", "Split", "Valuation"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "BioNTech (BNTX) Posts Strong Lung Cancer Data, Is It A Bargain?", "summary": "BioNTech (NasdaqGS:BNTX) moved after fresh clinical news, as investors reacted to detailed Phase 3 data showing its investigational lung cancer therapy gotistobart nearly doubled median overall survival compared with standard chemotherapy. At around US$96.69 per share, BioNTech has seen a 30 day share price return of 3.87% and a 90 day share price return of 4.85%, while the 1 year total shareholder return declined 2.59% and the 5 year total shareholder return fell 71.40%. This suggests that short term momentum has picked up even as long term holders have experienced heavy losses. Scan beyond B", "url": "https://finance.yahoo.com/healthcare/articles/biontech-bntx-posts-strong-lung-190825692.html", "source_link": "https://finance.yahoo.com/healthcare/articles/biontech-bntx-posts-strong-lung-190825692.html", "source_link_is_lookup": false, "source_name": "Simply Wall St.", "published_at": "2026-09-16T19:08:25+00:00", "published_display": "16 Sep 2026 19:08", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.010519, "evidence_share": 3.2, "evidence_share_display": "3.2", "freshness_pct": 9.3, "age_days": 24.0, "influence_label": "Low", "evidence_strength": 30, "duplicate_count": 2, "topics": ["Clinical Trials", "Earnings", "M A", "Oncology", "Pharma", "Revenue Growth"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech\u2019s Lung Cancer Drug Shows Signs of a Major Breakthrough", "summary": "BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need. The result builds on earlier Stage 1 data, where gotistobart red", "url": "https://finance.yahoo.com/healthcare/articles/biontech-lung-cancer-drug-shows-143753280.html", "source_link": "https://finance.yahoo.com/healthcare/articles/biontech-lung-cancer-drug-shows-143753280.html", "source_link_is_lookup": false, "source_name": "Insider Monkey", "published_at": "2026-09-15T14:37:53+00:00", "published_display": "15 Sep 2026 14:37", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.006863, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 8.2, "age_days": 25.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Balance Sheet", "Biotech", "Clinical Trials", "Lung Cancer", "Oncology", "Pharma"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech SE (BNTX) Gets a Buy from Morgan Stanley", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQaElWamdQcnVHVVRKUnZYeVRFOVRaeE4yTDFYdHpWYTdrQTdVUDEtOGdhV2JpWGg3V0xSNFZPSklWVzgtU0JKWFZMajBLME4zTFVBVEVoTUhkTDU2ajdXX0FoVDQwMlVBcTBiSFB6ODRJT2xVQVVERHdQbFE3UDl0TGN3a0s5VzRvbkJFZHFOUkRnVVk0TnBlOTk0YWc4VWNGVlBFbl9aWTdLN2lPYVBPdWJ2dktibFQ2dVlza3hvajcwOEZaTUwxTWdSNHk?oc=5", "source_link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQaElWamdQcnVHVVRKUnZYeVRFOVRaeE4yTDFYdHpWYTdrQTdVUDEtOGdhV2JpWGg3V0xSNFZPSklWVzgtU0JKWFZMajBLME4zTFVBVEVoTUhkTDU2ajdXX0FoVDQwMlVBcTBiSFB6ODRJT2xVQVVERHdQbFE3UDl0TGN3a0s5VzRvbkJFZHFOUkRnVVk0TnBlOTk0YWc4VWNGVlBFbl9aWTdLN2lPYVBPdWJ2dktibFQ2dVlza3hvajcwOEZaTUwxTWdSNHk?oc=5", "source_link_is_lookup": false, "source_name": "The Globe and Mail", "published_at": "2026-09-15T07:00:00+00:00", "published_display": "15 Sep 2026 07:00", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 9e-06, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.0, "age_days": 25.5, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Why Is BioNTech Stock Gaining Monday?", "summary": "On Monday, BioNTech SE(NASDAQ:BNTX) and OncoC4 Inc. released the first median overall survival results from stage 1 of their global PRESERVE-003 Phase 3 trial. The data indicate their investigational therapy nearly doubled survival times compared to standard chemotherapy for a specific patient population. Following the announcement, the stock jumped nearly 2%. Evaluating Gotistobart for Lung Cancer The study investigates gotistobart (BNT316 or ONC-392) for metastatic squamous non-small cell lung cancer (NSCLC). It focuses on patients whose cancer advanced despite prior immunotherapy and chemot", "url": "https://finance.yahoo.com/healthcare/articles/why-biontech-stock-gaining-monday-143512744.html", "source_link": "https://finance.yahoo.com/healthcare/articles/why-biontech-stock-gaining-monday-143512744.html", "source_link_is_lookup": false, "source_name": "Benzinga", "published_at": "2026-09-14T14:35:12+00:00", "published_display": "14 Sep 2026 14:35", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Positive market reaction", "Large positive market reaction"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.002231, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 2.6, "age_days": 26.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Biotech", "Clinical Trials", "Lung Cancer", "Pharma"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "BioNTech stock jumps on positive lung cancer trial data", "summary": "BioNTech's shares jumped after the company announced positive clinical trial data for its experimental lung cancer drug, gotistobart. The drug nearly doubled the median overall survival rate in patients with squamous non-small cell lung cancer compared to standard chemotherapy. This data comes from an ongoing Phase 3 trial and was presented at a major lung cancer conference.", "url": "https://m.investing.com/news/stock-market-news/biontech-stock-jumps-on-positive-lung-cancer-trial-data-93CH-4899652?ampMode=1", "source_link": "https://m.investing.com/news/stock-market-news/biontech-stock-jumps-on-positive-lung-cancer-trial-data-93CH-4899652?ampMode=1", "source_link_is_lookup": false, "source_name": "Investing.com", "published_at": "2026-09-14T12:37:06", "published_display": "14 Sep 2026 12:37", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "positive", "sentiment_pct": 71, "tone_signals": ["Positive market reaction"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 2.9e-05, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 26.3, "influence_label": "Medium", "evidence_strength": 45, "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech adds clinical weight to its oncology pivot at WCLC 2026", "summary": "BioNTech presented new clinical data at the World Conference on Lung Cancer (WCLC) in Seoul, bolstering its oncology strategy beyond its mRNA platform. The anti-CTLA-4 antibody gotistobart showed significant survival benefits in previously treated NSCLC, while the bispecific antibody pumitamig demonstrated encouraging signals across tumor types and in combination with an ADC. These developments highlight BioNTech's pivot towards a diverse, combination-driven oncology portfolio.", "url": "https://european-biotechnology.com/background/biontech-adds-clinical-weight-to-its-oncology-pivot-at-wclc-2026", "source_link": "https://european-biotechnology.com/background/biontech-adds-clinical-weight-to-its-oncology-pivot-at-wclc-2026", "source_link_is_lookup": false, "source_name": "European Biotechnology Magazine", "published_at": "2026-09-14T09:37:06", "published_display": "14 Sep 2026 09:37", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 6e-06, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.0, "age_days": 26.4, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients", "summary": "BioNTech SE Gotistobart continues to show potential aschemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current standard of care treatments is less than one year1 Gotistobart demonstrated a median overall survival of 18.5 months compared to 10.0 months with standard-of-care chemotherapy in updated data from stage 1 of the PRESERVE-003 Phase 3 clinical trial, nearly doubling median survival in this patient population Findings are consistent with gotistobart's differentiated mechanism ", "url": "https://finance.yahoo.com/healthcare/articles/biontech-oncoc4-present-updated-data-080000169.html", "source_link": "https://finance.yahoo.com/healthcare/articles/biontech-oncoc4-present-updated-data-080000169.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-09-14T08:00:00+00:00", "published_display": "14 Sep 2026 08:00", "source_kind": "press_release", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 5e-06, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.0, "age_days": 26.5, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Clinical Trials", "Immunotherapy", "Lung Cancer", "Pharma"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "BioNTech says lung cancer drug candidate prolonged lives in trial", "summary": "BioNTech announced that its drug candidate, gotistobart, significantly extended overall survival in patients with squamous non-small cell lung cancer whose disease had progressed despite prior immunotherapy and chemotherapy. Results from the PRESERVE-003 Phase 3 clinical trial showed that gotistobart nearly doubled survival compared to standard-of-care chemotherapy. This marks a clinically meaningful benefit for a specific type of lung cancer.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-says-lung-cancer-drug-candidate-prolonged-lives-trial-2026-09-14", "source_link": "https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-says-lung-cancer-drug-candidate-prolonged-lives-trial-2026-09-14", "source_link_is_lookup": false, "source_name": "Reuters", "published_at": "2026-09-14T08:07:00", "published_display": "14 Sep 2026 08:07", "source_kind": "editorial_wire", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 1.2e-05, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.0, "age_days": 26.5, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat", "summary": "Quick Read Moderna surges 8% while cancer-vaccine partner Merck slips 0.3% and peer BioNTech gains just 0.5%, pointing to a Moderna-specific momentum or short-squeeze event. XBI falls 0.1% and SPY rises less than 1%, eliminating both sector tailwinds and broad market strength as drivers of Moderna's rally. Already up 143% in a month on August's late-stage melanoma trial win, Moderna's latest jump has no new clinical, regulatory, or analyst trigger behind it. Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Merck didn't make the cut.", "url": "https://finance.yahoo.com/markets/stocks/articles/moderna-rallies-8-2026-melt-155630208.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/moderna-rallies-8-2026-melt-155630208.html", "source_link_is_lookup": false, "source_name": "24/7 Wall St.", "published_at": "2026-09-11T15:56:30+00:00", "published_display": "11 Sep 2026 15:56", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 2e-06, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.0, "age_days": 29.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Biotech", "Cancer Vaccine", "Momentum", "Price Target"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech (BNTX) Stock Stays Rich On Sales As Revenue Looks Weaker", "summary": "", "url": "https://news.google.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?oc=5", "source_link": "https://news.google.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?oc=5", "source_link_is_lookup": false, "source_name": "simplywall.st", "published_at": "2026-09-11T10:29:51+00:00", "published_display": "11 Sep 2026 10:29", "source_kind": "publisher", "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001607, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 1.7, "age_days": 29.4, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": false}], "by_tier": {"direct": [{"title": "Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/moderna-climbs-5-nasdaq-100-154854096.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/moderna-climbs-5-nasdaq-100-154854096.html", "source_link_is_lookup": false, "source_name": "24/7 Wall St.", "published_at": "2026-10-09T15:48:54+00:00", "published_display": "09 Oct 2026 15:48", "provider": "yfinance", "providers": ["yfinance"], "provider_symbol": "", "provider_symbols": ["BNTX", "IBB", "MRNA", "PFE", "SPY", "^NDX"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["24/7 Wall St."], "source_kind": "publisher", "story_key": "58838a34ce62afa94b0c32222c146874491e5fa7b2cb448259e64f2dbebf6d8b", "target_scope": "Pfizer Inches Higher, BioNTech Ticks Up", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.72, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.029948, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 66.5, "age_days": 1.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech SE (BNTX) Stock Price, News, Quote & History", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE44WWdPd1J3d2lqbnFNcndSVkxIWUJiNXVDdWhhVEVtYzhCbU83NU8tWlhfd3JualBnSE92NkFZTHlrTHkwQ3ZiMG5tRGx4STRRSVE?oc=5", "source_link": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE44WWdPd1J3d2lqbnFNcndSVkxIWUJiNXVDdWhhVEVtYzhCbU83NU8tWlhfd3JualBnSE92NkFZTHlrTHkwQ3ZiMG5tRGx4STRRSVE?oc=5", "source_link_is_lookup": false, "source_name": "Yahoo! Finance Canada", "published_at": "2026-10-09T11:05:36+00:00", "published_display": "09 Oct 2026 11:05", "provider": "google_news", "providers": ["archive", "google_news"], "provider_symbol": "", "provider_symbols": ["BNTX.ARCHIVE"], "target_provider_symbol": "BNTX.ARCHIVE", "cross_listing": false, "source_names": ["Market source", "Yahoo! Finance Canada"], "source_kind": "publisher", "story_key": "d8baf06996029c8054d8727c53897eb6c766db2aed3758f402d93d5ebb66387b", "target_scope": "BioNTech SE (BNTX) Stock Price, News, Quote & History", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.038228, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 62.2, "age_days": 1.4, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": [], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100?", "summary": "BioNTech is transitioning from a COVID-19 vaccine producer to a major oncology company, with a robust late-stage cancer pipeline that includes over 25 phase 2 and phase 3 trials. Its lead candidate, pumitamig, is being tested across multiple solid tumor types, and the company plans to have 15 phase 3 trials by 2026. Despite a recent revenue drop, BioNTech's strong balance sheet and diversified pipeline suggest significant upside potential, making its current stock price under $100 an attractive entry point for investors.", "url": "https://www.fool.com/investing/2026/10/08/biontech-has-more-cancer-drugs-in-late-stage-trial", "source_link": "https://www.fool.com/investing/2026/10/08/biontech-has-more-cancer-drugs-in-late-stage-trial", "source_link_is_lookup": false, "source_name": "The Motley Fool", "published_at": "2026-10-08T17:34:42", "published_display": "08 Oct 2026 17:34", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["BMY", "BNTX"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["The Globe and Mail", "The Motley Fool"], "source_kind": "publisher", "story_key": "ecb39d5aafd7c817fa20bbefbf8dc7b74b2ad61c4cce0254efacb8cacf40aef8", "target_scope": "BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. BioNTech is transitioning from a COVID-19 vaccine producer to a major oncology company, with a robust late-stage cancer pipeline that includes over 25 phase 2 and phase 3 trials. but Its lead candidate, pumitamig, is being tested across multiple solid tumor types, and the company plans to have 15 phase 3 trials by 2026. Despite a recent revenue drop, BioNTech's strong balance sheet and diversified pipeline suggest significant upside potential, making its current stock price under $100 an attractive entry point for investors.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.611, "provider_directional_mass": 0.4352, "relevance_score": 1.0, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.495, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Operating deterioration", "Positive valuation view"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.114811, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 74.7, "age_days": 2.1, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Finance", "Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Is BioNTech (BNTX) Undervalued On Pipeline Promise Despite Revenue Of \u20ac2,650.0 Million And Losses?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNNzV4OTZiTERERE5DamJ4WkszMzRUSnJVNlpUT0Q0d3JBbHE3UnpDX09wM0xDTDFqRFlNTzhFNzM2d2lwVEZZc2w0VjczeVY1c0RNQ1hhdVBEUm5hRFh3ZlRMUnF3d0F0amhtVkxDMWE4UW56cmk2dVItZjE0VXRGcVFnWVJpcEd4OE13LUtEc3g2a0hkZDVzRzAtTTh3Q2N1R3ZhWTZKajhfd2dTWWFsU0w1N3d4MjBKMU96aFNwS1Z5YTMyX1V4bFF3OWZqU2ZMRFBsTFJSNkRfQdIB3wFBVV95cUxONXlsU08zcnZoTk1telNzTDl4bVlMTUxXYUQ4S1I5WFh1UXExaWNFRUlRX3E4NWRnMjdvN2Vjd1ZhQ05IQmp2REVfdkRrSVlpV3VPdXJHa2E2SElrYXlHYmpiaHA4VTBzcWtnbzFUWU94VWpkeE5VYkk2b1Rza1I0OE1ZX1Z2WF9URUdJejZ1NkFCMVdKaFIwMG1fN2EyaXhSZVIwUC1mZk1iRHVlcXZROXI3SEhZYk4yOU5meTZSWm9ZRVZUWFp4RGxDaW5VWHhneTdiUzZrWGhheW5QSV9v?oc=5", "source_link": "https://news.google.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?oc=5", "source_link_is_lookup": false, "source_name": "Simply Wall Street", "published_at": "2026-10-08T04:03:31+00:00", "published_display": "08 Oct 2026 04:03", "provider": "google_news", "providers": ["archive", "google_news"], "provider_symbol": "", "provider_symbols": ["BNTX.ARCHIVE"], "target_provider_symbol": "BNTX.ARCHIVE", "cross_listing": false, "source_names": ["Simply Wall Street"], "source_kind": "publisher", "story_key": "7a1eb4a7bd598df305ee79af6b64ccaf3e766059e2c47ac3f77497a56eb36e19", "target_scope": "Is BioNTech (BNTX) Undervalued On Pipeline Promise Despite Revenue Of \u20ac2,650.0 Million And Losses?", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.475, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.812, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Positive valuation view"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.067521, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 69.1, "age_days": 2.7, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Is BioNTech (NasdaqGS:BNTX) Overvalued As Sales Face A Reset?", "summary": "BioNTech has seen its share price slide over recent years while the business reshapes itself beyond the COVID-19 vaccine boom, which naturally puts the focus back on what investors are paying for its current and potential sales base. With market sentiment shifting around the restructuring of its manufacturing footprint and the oncology pipeline, the live question is how well the present US$95.73 price lines up with the revenue the company is generating and expects to generate. The stock has fallen 60.3% over 5 years, which raises the issue of whether the market is now pricing BioNTech more on ", "url": "https://finance.yahoo.com/markets/stocks/articles/biontech-nasdaqgs-bntx-overvalued-sales-211241777.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/biontech-nasdaqgs-bntx-overvalued-sales-211241777.html", "source_link_is_lookup": false, "source_name": "Simply Wall St.", "published_at": "2026-10-07T21:12:41+00:00", "published_display": "07 Oct 2026 21:12", "provider": "yfinance", "providers": ["archive", "eodhd", "yfinance"], "provider_symbol": "B1NT34.SA", "provider_symbols": ["BNTX", "BNTX.ARCHIVE", "BNTX.US", "PFE", "PFE.DU", "PFE.MU", "PFE.US"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Simply Wall St.", "finance.yahoo.com"], "source_kind": "publisher", "story_key": "b7c97a6ad23d19500a559195038c1f91d1621178a134d7d2749b47751f70a90f", "target_scope": "Is BioNTech (NasdaqGS:BNTX) Overvalued As Sales Face A Reset? BioNTech has seen its share price slide over recent years The stock has fallen 60.3% over 5 years, which raises the issue of whether the market is now pricing BioNTech more on", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.54, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.157, "sentiment": "neutral", "sentiment_pct": 45, "tone_signals": ["Negative valuation view", "Negative market reaction"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.022805, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 36.0, "age_days": 3.0, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Biotech", "Earnings", "Oncology", "Restructuring", "Share Price", "Valuation"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Under a prearranged trading plan, BioNTech (BNTX) CEO Ugur Sahin sells 24,000 shares.", "summary": "BioNTech CEO Ugur Sahin sold 24,000 ordinary shares at $95.8597 per share on October 7, 2026, through a pre-established Rule 10b5-1 trading plan. After the sale, his direct holdings amounted to 63,209 ordinary shares. Additionally, 39,218,111 ordinary shares are held indirectly through Medine GmbH, a company wholly owned by Sahin.", "url": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-160388166f17.html", "source_link": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-160388166f17.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-10-07T21:28:47", "published_display": "07 Oct 2026 21:28", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["BNTX"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Stock Titan"], "source_kind": "publisher", "story_key": "573a9f3fd606ddc477923b743755036a81a593a2100c620bb1927b69a34c631c", "target_scope": "Under a prearranged trading plan, BioNTech (BNTX) CEO Ugur Sahin sells 24,000 shares. BioNTech CEO Ugur Sahin sold 24,000 ordinary shares at $95.8597 per share on October 7, 2026, through a pre-established Rule 10b5-1 trading plan.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.694, "provider_directional_mass": 0.2858, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 40, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.050869, "evidence_share": 15.4, "evidence_share_display": "15.4", "freshness_pct": 36.1, "age_days": 2.9, "influence_label": "Medium", "evidence_strength": 43, "duplicate_count": 1, "topics": ["Life Sciences", "Financial Markets", "Finance", "Earnings"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech SE : Gets a Buy rating from Berenberg", "summary": "Berenberg has reiterated its \"Buy\" rating for BioNTech SE, with analyst Luisa Hector maintaining a positive outlook on the stock. The target price for BioNTech SE shares remains set at USD 140. This news was published on October 7, 2026.", "url": "https://www.marketscreener.com/news/biontech-se-gets-a-buy-rating-from-berenberg-ce785dd9d089f322", "source_link": "https://www.marketscreener.com/news/biontech-se-gets-a-buy-rating-from-berenberg-ce785dd9d089f322", "source_link_is_lookup": false, "source_name": "marketscreener.com", "published_at": "2026-10-07T08:24:50", "published_display": "07 Oct 2026 08:24", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["BNTX"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["marketscreener.com"], "source_kind": "publisher", "story_key": "ebf4ef688b50f097b4554f112b8fe83d588d8405d5ee61c421ccb49f1e763379", "target_scope": "BioNTech SE : Gets a Buy rating from Berenberg Berenberg has reiterated its \"Buy\" rating for BioNTech SE, with analyst Luisa Hector maintaining a positive outlook on the stock. The target price for BioNTech SE shares remains set at USD 140.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.645, "provider_directional_mass": 0.4294, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 69, "tone_signals": ["Buy Rating"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.087554, "evidence_share": 26.5, "evidence_share_display": "26.5", "freshness_pct": 44.7, "age_days": 3.5, "influence_label": "Medium", "evidence_strength": 54, "duplicate_count": 1, "topics": ["Life Sciences", "Financial Markets"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "Biontech Insider Sold Shares Worth $9,033,642, According to a Recent SEC Filing", "summary": "A recent SEC filing indicates that an insider at BioNTech (BNTX) sold shares valued at $9,033,642. This transaction is part of a series of insider share sales for the company, with previous sales noted on September 11th and September 8th. BioNTech is a German biotechnology company specializing in patient-specific immunotherapies for cancer and other serious diseases.", "url": "https://www.marketscreener.com/news/biontech-insider-sold-shares-worth-9-033-642-according-to-a-recent-sec-filing-ce785dd9dc81f322", "source_link": "https://www.marketscreener.com/news/biontech-insider-sold-shares-worth-9-033-642-according-to-a-recent-sec-filing-ce785dd9dc81f322", "source_link_is_lookup": false, "source_name": "www.marketscreener.com", "published_at": "2026-10-06T21:01:04", "published_display": "06 Oct 2026 21:01", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["BNTX"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["www.marketscreener.com"], "source_kind": "publisher", "story_key": "4bb0cad81e6717ba0b980119ef37ad2d4d96286027d276f6128d5f5be2313f75", "target_scope": "Biontech Insider Sold Shares Worth $9,033,642, According to a Recent SEC Filing A recent SEC filing indicates that an insider at BioNTech (BNTX) sold shares valued at $9,033,642. BioNTech is a German biotechnology company specializing in patient-specific immunotherapies for cancer and other serious diseases.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.694, "provider_directional_mass": 0.2614, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 40, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.035731, "evidence_share": 10.8, "evidence_share_display": "10.8", "freshness_pct": 25.4, "age_days": 4.0, "influence_label": "Medium", "evidence_strength": 40, "duplicate_count": 1, "topics": ["Life Sciences", "Earnings"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/moderna-surges-8-full-melanoma-184702779.html", "source_link": "https://finance.yahoo.com/healthcare/articles/moderna-surges-8-full-melanoma-184702779.html", "source_link_is_lookup": false, "source_name": "24/7 Wall St.", "published_at": "2026-10-05T18:47:02+00:00", "published_display": "05 Oct 2026 18:47", "provider": "yfinance", "providers": ["archive", "yfinance"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE", "IBB", "MRK", "MRNA", "PFE", "SPY"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["24/7 Wall St."], "source_kind": "publisher", "story_key": "fad0ad736feef952996a0e17fa571a12a24ca6516382d26a10f20df633074bad", "target_scope": "BioNTech Ticks Up, Pfizer Slips", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.008188, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 17.4, "age_days": 5.1, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech stock draws Moderate Buy consensus at USD 126 target", "summary": "BioNTech stock received a \"Moderate Buy\" consensus from 19 brokerages with an average target price of USD 126, despite a challenging second quarter that saw significant GAAP net losses. While analysts anticipate a higher valuation, the company's financial performance highlights its dependence on its oncology pipeline as COVID-19 vaccine revenue decreases. The stock's current trading price of USD 97.10 is 29.7% below the analyst target and USD 26.90 below its 52-week high of USD 124.00.", "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/biontech-stock-draws-moderate-buy-consensus-at-usd-126-target/70234906", "source_link": "https://www.ad-hoc-news.de/boerse/news/corporate-news/biontech-stock-draws-moderate-buy-consensus-at-usd-126-target/70234906", "source_link_is_lookup": false, "source_name": "AD HOC NEWS", "published_at": "2026-10-05T18:26:00", "published_display": "05 Oct 2026 18:26", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["AD HOC NEWS"], "source_kind": "publisher", "story_key": "afab859362ec96375c66ff0c314dc5812047262557af61c00eede5d804e588b5", "target_scope": "BioNTech stock draws Moderate Buy consensus at USD 126 target BioNTech stock received a \"Moderate Buy\" consensus from 19 brokerages with an average target price of USD 126, despite a challenging second quarter that saw significant GAAP net losses.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.511, "provider_directional_mass": 0.148, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Negative financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.060761, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 49.5, "age_days": 5.1, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech (BNTX) CEO Ugur Sahin sells 72,000 and 21,000 shares under a June 3 trading plan.", "summary": "BioNTech CEO Ugur Sahin reported direct sales of 72,000 ordinary shares on October 5, 2026, at $97.2312 per share and 21,000 ordinary shares on October 6, 2026, at $96.8093 per share. These transactions were executed under a Rule 10b5-1 trading plan established on June 3, 2026. Sahin's indirect holdings through Medine GmbH, where he is the sole shareholder, amount to 39,218,111 shares.", "url": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-14b0b2b132d1.html", "source_link": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-14b0b2b132d1.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-10-05T09:28:47", "published_display": "05 Oct 2026 09:28", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["BNTX"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Stock Titan"], "source_kind": "publisher", "story_key": "5336bb70dfb6da0c7c13ff8361517266dce58593a6b6f8ee0996b630686fd50d", "target_scope": "BioNTech (BNTX) CEO Ugur Sahin sells 72,000 and 21,000 shares under a June 3 trading plan. BioNTech CEO Ugur Sahin reported direct sales of 72,000 ordinary shares on October 5, 2026, at $97.2312 per share and 21,000 ordinary shares on October 6, 2026, at $96.8093 per share.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.599, "provider_directional_mass": 0.3858, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 42, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.017498, "evidence_share": 5.3, "evidence_share_display": "5.3", "freshness_pct": 15.2, "age_days": 5.4, "influence_label": "Low", "evidence_strength": 34, "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech to close three German sites. BioNTech stock costs EUR 86.10 in weekend trading", "summary": "BioNTech announced it would close three German sites after failing to sell them, marking a shift away from pandemic-era manufacturing. The company's stock was trading at EUR 86.10 in weekend trading, matching its previous closing price. This news follows a recent release of updated trial data for their cancer treatment, gotistobart, showing promising results.", "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/biontech-to-close-three-german-sites-biontech-stock-costs-eur-86-10-in/70220956", "source_link": "https://www.ad-hoc-news.de/boerse/news/corporate-news/biontech-to-close-three-german-sites-biontech-stock-costs-eur-86-10-in/70220956", "source_link_is_lookup": false, "source_name": "AD HOC NEWS", "published_at": "2026-10-03T13:00:00", "published_display": "03 Oct 2026 13:00", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["AD HOC NEWS"], "source_kind": "publisher", "story_key": "3bd50d2a7c05c7e6b4c77607cedc5006f36b22fb1d41ca66896676268e9f3008", "target_scope": "BioNTech to close three German sites. BioNTech stock costs EUR 86.10 in weekend trading BioNTech announced it would close three German sites after failing to sell them, marking a shift away from pandemic-era manufacturing. but The company's stock was trading at EUR 86.10 in weekend trading, matching its previous closing price.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": 0.2952, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.005731, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 8.0, "age_days": 7.3, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences", "Manufacturing"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech SE (BNTX) options chain \u2013 Yahoo Finance", "summary": "This page from Yahoo Finance provides information on BioNTech SE (BNTX), including its stock summary, news, chart, statistics, historical data, profile, financials, analysis, options, and holders. It notes the current stock price and highlights that there are no options listed for the company at this time.", "url": "https://sg.finance.yahoo.com/quote/BNTX/options?date=1826582400&straddle=true", "source_link": "https://sg.finance.yahoo.com/quote/BNTX/options?date=1826582400&straddle=true", "source_link_is_lookup": false, "source_name": "Market source", "published_at": "2026-10-03T05:01:04", "published_display": "03 Oct 2026 05:01", "provider": "alphavantage", "providers": ["alphavantage"], "provider_symbol": "", "provider_symbols": ["BNTX"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Market source"], "source_kind": "aggregator", "story_key": "48e187bd9ab749a4b66dca1e7c16256ab5852b7953534f4f8016775e51d2fd9d", "target_scope": "BioNTech SE (BNTX) options chain This page from Yahoo Finance provides information on BioNTech SE (BNTX), including its stock summary, news, chart, statistics, historical data, profile, financials, analysis, options, and holders. but It notes the current stock price and highlights that there are no options listed for the company at this time.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": 0.0006, "relevance_score": 0.72, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.00383, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 7.1, "age_days": 7.6, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech (BNTX) CEO sells 17,000 shares twice under a preset trading plan", "summary": "BioNTech CEO Ugur Sahin sold 17,000 ordinary shares on October 1, 2026, at $97.4556 per share, and another 17,000 shares on October 2, 2026, at $96.7249 per share. These sales were executed under a pre-established Rule 10b5-1 trading plan. Sahin also holds a significant indirect stake of 39,218,111 shares through Medine GmbH, where he is the sole shareholder, with a portion of these held in a trust arrangement.", "url": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-b0c5f8cc0bb7.html", "source_link": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-b0c5f8cc0bb7.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-10-02T20:34:37", "published_display": "02 Oct 2026 20:34", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Stock Titan"], "source_kind": "publisher", "story_key": "8958e1194d5c1e57d1ae5fc420a2627a386691690b79ec4b94c1c2fa5b9af5ae", "target_scope": "BioNTech (BNTX) CEO sells 17,000 shares twice under a preset trading plan BioNTech CEO Ugur Sahin sold 17,000 ordinary shares on October 1, 2026, at $97.4556 per share, and another 17,000 shares on October 2, 2026, at $96.7249 per share.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.694, "provider_directional_mass": 0.2011, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 40, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.008876, "evidence_share": 2.7, "evidence_share_display": "2.7", "freshness_pct": 6.3, "age_days": 8.0, "influence_label": "Low", "evidence_strength": 35, "duplicate_count": 1, "topics": ["Finance", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech SE (BNTX) Stock Price, News, Quote & History", "summary": "This Yahoo Finance page provides comprehensive financial information for BioNTech SE (22UA.F), including its current stock price, historical data, and key statistics. It details the company's overview as a biotechnology firm involved in developing immunotherapies, particularly its SARS-CoV-2 vaccine and various oncology drugs in clinical trials. The article also presents performance metrics, earnings trends, and valuation measures for BioNTech SE.", "url": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE44WWdPd1J3d2lqbnFNcndSVkxIWUJiNXVDdWhhVEVtYzhCbU83NU8tWlhfd3JualBnSE92NkFZTHlrTHkwQ3ZiMG5tRGx4STRRSVE?oc=5", "source_link": "https://news.google.com/rss/articles/CBMiUkFVX3lxTE44WWdPd1J3d2lqbnFNcndSVkxIWUJiNXVDdWhhVEVtYzhCbU83NU8tWlhfd3JualBnSE92NkFZTHlrTHkwQ3ZiMG5tRGx4STRRSVE?oc=5", "source_link_is_lookup": false, "source_name": "Yahoo! Finance Canada", "published_at": "2026-10-01T16:05:42+00:00", "published_display": "01 Oct 2026 16:05", "provider": "archive", "providers": ["alphavantage", "archive", "google_news"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE", "MRNA"], "target_provider_symbol": "BNTX.ARCHIVE", "cross_listing": false, "source_names": ["Market source", "Yahoo! Finance Canada"], "source_kind": "publisher", "story_key": "d8baf06996029c8054d8727c53897eb6c766db2aed3758f402d93d5ebb66387b", "target_scope": "BioNTech SE (BNTX) Stock Price, News, Quote & History This Yahoo Finance page provides comprehensive financial information for BioNTech SE (22UA.F), including its current stock price, historical data, and key statistics. but It details the company's overview as a biotechnology firm involved in developing immunotherapies, particularly its SARS-CoV-2 vaccine and various oncology drugs in clinical trials. The article also presents performance metrics, earnings trends, and valuation measures for BioNTech SE.", "durable_archive": true, "archive_provider": "google_news", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 1.0, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.023762, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 28.1, "age_days": 9.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "Moderna Climbs 3% Despite Citigroup\u2019s Downgrade to Sell; BioNTech Inches Higher, Pfizer Treads Water", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/moderna-climbs-3-despite-citigroup-150011294.html", "source_link": "https://finance.yahoo.com/healthcare/articles/moderna-climbs-3-despite-citigroup-150011294.html", "source_link_is_lookup": false, "source_name": "24/7 Wall St.", "published_at": "2026-10-01T15:00:11+00:00", "published_display": "01 Oct 2026 15:00", "provider": "yfinance", "providers": ["archive", "yfinance"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE", "C", "IBB", "MRK", "MRNA", "PFE", "SPY"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["24/7 Wall St."], "source_kind": "publisher", "story_key": "9238e4fd1b8182918c37bafe13284d7bc4ea0e15c83b215079cb685a634e601a", "target_scope": "BioNTech Inches Higher, Pfizer Treads Water", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001938, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 4.1, "age_days": 9.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Under a June 3 trading plan, BioNTech (BNTX) CEO Ugur Sahin sells 34,000 and 32,000 shares.", "summary": "BioNTech CEO Ugur Sahin reported direct sales of 34,000 ordinary shares at $98.2591 and 32,000 ordinary shares at $98.1203 on September 29 and September 30, 2026, respectively. These transactions were executed under a Rule 10b5-1 trading plan established on June 3, 2026. Sahin also indirectly beneficially owns 39,218,111 ordinary shares through Medine GmbH, which holds voting power over 106,721 shares in a trust for an individual.", "url": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-3d6c943e4876.html", "source_link": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-3d6c943e4876.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-09-30T20:27:06", "published_display": "30 Sep 2026 20:27", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Stock Titan"], "source_kind": "publisher", "story_key": "eceae8b097158787c7390f9fd428c4b352507db66bf16396cd6068ccf94c6cea", "target_scope": "Under a June 3 trading plan, BioNTech (BNTX) CEO Ugur Sahin sells 34,000 and 32,000 shares. BioNTech CEO Ugur Sahin reported direct sales of 34,000 ordinary shares at $98.2591 and 32,000 ordinary shares at $98.1203 on September 29 and September 30, 2026, respectively.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.599, "provider_directional_mass": 0.246, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 42, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.003624, "evidence_share": 1.1, "evidence_share_display": "1.1", "freshness_pct": 3.1, "age_days": 10.0, "influence_label": "Low", "evidence_strength": 31, "duplicate_count": 1, "topics": ["Earnings", "Finance", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech Steps Deeper Into Lung Cancer With New Dareon-Rosetta35 Trial", "summary": "BioNTech announced the Dareon-Rosetta35 trial, a Phase Ib/II study evaluating new cancer drugs, obrixtamig and pumitamig, for advanced small cell lung cancer. This trial, a partnership with Boehringer Ingelheim, aims to assess drug tolerability and tumor response, marking BioNTech's expansion into solid tumors beyond vaccines. The study is interventional and open-label, focusing on safety and early signs of efficacy, and could provide a new revenue stream for BNTX if successful.", "url": "https://www.tipranks.com/news/company-announcements/biontech-steps-deeper-into-lung-cancer-with-new-dareon-rosetta35-trial", "source_link": "https://www.tipranks.com/news/company-announcements/biontech-steps-deeper-into-lung-cancer-with-new-dareon-rosetta35-trial", "source_link_is_lookup": false, "source_name": "TipRanks", "published_at": "2026-09-30T16:27:06", "published_display": "30 Sep 2026 16:27", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["TipRanks"], "source_kind": "publisher", "story_key": "b958cc11e31b3f2886d6fcb88c2349c0e1fb3ef1afa834efdafee10fa9b2be71", "target_scope": "BioNTech Steps Deeper Into Lung Cancer With New Dareon-Rosetta35 Trial BioNTech announced the Dareon-Rosetta35 trial, a Phase Ib/II study evaluating new cancer drugs, obrixtamig and pumitamig, for advanced small cell lung cancer. This trial, a partnership with Boehringer Ingelheim, aims to assess drug tolerability and tumor response, marking BioNTech's expansion into solid tumors beyond vaccines. The study is interventional and open-label, focusing on safety and early signs of efficacy, and could provide a new revenue stream for BNTX if successful.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": 0.0102, "relevance_score": 0.78, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.027033, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 24.5, "age_days": 10.1, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Moderna vs. BioNTech: Which mRNA Stock Is the Better Buy Now?", "summary": "Moderna (MRNA) and BioNTech (BNTX), both prominent in mRNA technology, are transitioning from COVID-19 vaccine reliance to developing new therapies. Moderna appears to be further along in this diversification, with approved respiratory vaccines and positive late-stage oncology results. BioNTech, while having a broader oncology pipeline, faces greater challenges with revenue replacement as COVID-19 vaccine demand normalizes and has experienced recent clinical setbacks.", "url": "https://finance.yahoo.com/healthcare/articles/moderna-vs-biontech-mrna-stock-150100907.html", "source_link": "https://finance.yahoo.com/healthcare/articles/moderna-vs-biontech-mrna-stock-150100907.html", "source_link_is_lookup": false, "source_name": "Zacks", "published_at": "2026-09-30T15:01:00+00:00", "published_display": "30 Sep 2026 15:01", "provider": "yfinance", "providers": ["alphavantage", "archive", "eodhd", "yfinance"], "provider_symbol": "B1NT34.SA", "provider_symbols": ["BMY", "BNTX", "BNTX.ARCHIVE", "BNTX.US", "MRK", "MRK.US", "MRNA", "MRNA.US", "PFE", "PFE.US"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["TradingView", "Zacks", "finance.yahoo.com"], "source_kind": "publisher", "story_key": "0f4dc69d3504030a74727837135292580e834fe1c0b24e03e703589e0a5806db", "target_scope": "BioNTech: Which mRNA Stock Is the Better Buy Now? Moderna (MRNA) and BioNTech (BNTX), both prominent in mRNA technology, are transitioning from COVID-19 vaccine reliance to developing new therapies. BioNTech,", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 1.0, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001866, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 2.9, "age_days": 10.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 3, "topics": ["Biotech", "Covid 19", "Earnings", "Financial Markets", "Life Sciences", "Oncology"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech stock trades at EUR 86.05 after a revenue miss", "summary": "BioNTech's stock is trading at EUR 86.05 following a significant revenue miss in Q2 2026, with revenue dropping by 59.50% to EUR 105.6 million. The company also reported a GAAP net loss and reduced its full-year revenue guidance, as its transition from COVID vaccine revenue to oncology growth faces challenges, including the termination of a Phase 2 colorectal cancer trial. Despite these setbacks, Berenberg raised its price target for BioNTech to USD 140.00 with a Buy rating.", "url": "https://www.ad-hoc-news.de/boerse/news/corporate-news/biontech-stock-trades-at-eur-86-05-after-a-revenue-miss/70205151", "source_link": "https://www.ad-hoc-news.de/boerse/news/corporate-news/biontech-stock-trades-at-eur-86-05-after-a-revenue-miss/70205151", "source_link_is_lookup": false, "source_name": "AD HOC NEWS", "published_at": "2026-09-30T14:32:28", "published_display": "30 Sep 2026 14:32", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["AD HOC NEWS"], "source_kind": "publisher", "story_key": "a5b56780f921033a91cefaaaaf8fd48ca095517bc19bf1b646ea9a26529e58c4", "target_scope": "BioNTech stock trades at EUR 86.05 after a revenue miss BioNTech's stock is trading at EUR 86.05 following a significant revenue miss in Q2 2026, with revenue dropping by 59.50% to EUR 105.6 million. but The company also reported a GAAP net loss and reduced its full-year revenue guidance, as its transition from COVID vaccine revenue to oncology growth faces challenges, including the termination of a Phase 2 colorectal cancer trial. Despite these setbacks, Berenberg raised its price target for BioNTech to USD 140.00 with a Buy rating.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.86, "provider_directional_mass": 0.2086, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.268, "sentiment": "negative", "sentiment_pct": 21, "tone_signals": ["Missed expectations", "Guidance cut"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.029271, "evidence_share": 8.9, "evidence_share_display": "8.9", "freshness_pct": 9.4, "age_days": 10.2, "influence_label": "High", "evidence_strength": 58, "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech (NasdaqGS:BNTX) Stock Forecast & Analyst Predictions", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQRXJseEVnMTg5RXZ5M0p5Zml4QlZDdG9HdjdTeXRUWWpGa3ZabW5QNk85bGlrN3RSQ29uWXJrcFY5cVV3eWEwZ3BDT0xrbFJ2UjFaa1l1bE54cTFTSG5TMzl1dy1zdmxKVWNyQ3FPMm9FQlJpV3RFSjNsWXdSZGVmUk1YM05VVlFPbFZv?oc=5", "source_link": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxQRXJseEVnMTg5RXZ5M0p5Zml4QlZDdG9HdjdTeXRUWWpGa3ZabW5QNk85bGlrN3RSQ29uWXJrcFY5cVV3eWEwZ3BDT0xrbFJ2UjFaa1l1bE54cTFTSG5TMzl1dy1zdmxKVWNyQ3FPMm9FQlJpV3RFSjNsWXdSZGVmUk1YM05VVlFPbFZv?oc=5", "source_link_is_lookup": false, "source_name": "Simply Wall Street", "published_at": "2026-09-30T07:00:00+00:00", "published_display": "30 Sep 2026 07:00", "provider": "archive", "providers": ["archive", "google_news"], "provider_symbol": "", "provider_symbols": ["BNTX.ARCHIVE"], "target_provider_symbol": "BNTX.ARCHIVE", "cross_listing": false, "source_names": ["Simply Wall Street"], "source_kind": "publisher", "story_key": "a16965c276e8025bfcb6ab2f8c6601f0f541b768b5daac1b76c2588fc2d1a0c7", "target_scope": "BioNTech (NasdaqGS:BNTX) Stock Forecast & Analyst Predictions", "durable_archive": true, "archive_provider": "google_news", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.039973, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 35.2, "age_days": 10.5, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": false}, {"title": "Pfizer, BioNTech, Moderna dealt blow in effort to dismiss mRNA patent lawsuits", "summary": "[Intellectual Property mind map diagram with patent, trademark, copyright, license, infringement, trade secret on notepad] Ployker/iStock via Getty Images * A Delaware federal judge on Monday rejected requests from Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), BioNTech (BNTX [https://seekingalpha.com/symbol/BNTX]), and Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) to dismiss lawsuits filed against them by Bayer's (BAYZF [https://seekingalpha.com/symbol/BAYZF])(BAYRY [https://seekingalpha.com/symbol/BAYRY]) Monsanto unit regarding the drugmakers' use of a patent related to mRNA te", "url": "https://seekingalpha.com/news/4647773-pfizer-biontech-moderna-dealt-blow-effort-dismiss-mrna-patent-lawsuits?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link": "https://seekingalpha.com/news/4647773-pfizer-biontech-moderna-dealt-blow-effort-dismiss-mrna-patent-lawsuits?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "source_link_is_lookup": false, "source_name": "seekingalpha.com", "published_at": "2026-09-28T20:38:01+00:00", "published_display": "28 Sep 2026 20:38", "provider": "eodhd", "providers": ["archive", "eodhd"], "provider_symbol": "BNTX.US", "provider_symbols": ["BAYRY.US", "BAYZF.US", "BNTX.ARCHIVE", "BNTX.US", "JNJ.US", "MRNA.US", "PFE.US"], "target_provider_symbol": "BNTX.US", "cross_listing": false, "source_names": ["seekingalpha.com"], "source_kind": "publisher", "story_key": "66c3ca867797cea00650cf5e786f840b5c3002f12e0cf01f0af30ea377329adb", "target_scope": "Pfizer, BioNTech, Moderna dealt blow in effort to dismiss mRNA patent lawsuits [Intellectual Property mind map diagram with patent, trademark, copyright, license, infringement, trade secret on notepad] Ployker/iStock via Getty Images * A Delaware federal judge on Monday rejected requests from Pfizer (PFE [https://seekingalpha.com/symbol/PFE]), BioNTech (BNTX [https://seekingalpha.com/symbol/BNTX]), and Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) to dismiss lawsuits filed against them by Bayer's (BAYZF [https://seekingalpha.com/symbol/BAYZF])(BAYRY [https://seekingalpha.com/symbol/BAYRY]) Monsanto unit regarding the drugmakers' use of a patent related to mRNA te", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": 0.141, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.025486, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 30.6, "age_days": 12.0, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Biotech", "M A", "Patent Dispute", "Vaccines"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "A trading plan covers BioNTech (BNTX) CEO Ugur Sahin's sales of 27,000 and 34,000 shares.", "summary": "BioNTech CEO Ugur Sahin reported direct sales of 27,000 ordinary shares on September 25, 2026, and 34,000 ordinary shares on September 28, 2026, both executed under a Rule 10b5-1 trading plan established in June 2026. The sales were priced at $98.6882 and $98.4682 per share, respectively. Sahin retains significant indirect holdings through Medine GmbH.", "url": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-31a9faabda7c.html", "source_link": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-31a9faabda7c.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-09-28T21:23:36", "published_display": "28 Sep 2026 21:23", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Stock Titan"], "source_kind": "publisher", "story_key": "9ffec915ded612db7414f82455164de2e14ff42b13efb1df0cbc0c46d69a92b4", "target_scope": "A trading plan covers BioNTech (BNTX) CEO Ugur Sahin's sales of 27,000 and 34,000 shares. BioNTech CEO Ugur Sahin reported direct sales of 27,000 ordinary shares on September 25, 2026, and 34,000 ordinary shares on September 28, 2026, both executed under a Rule 10b5-1 trading plan established in June 2026.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": 0.2208, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001144, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 1.6, "age_days": 11.9, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech to Close 3 German Sites After Unsuccessful Sale Efforts", "summary": "BioNTech announced it will close three German sites after failing to sell them. The company, known for its COVID-19 vaccine, has been restructuring and adjusting its operations. This move reflects ongoing efforts to optimize its asset portfolio.", "url": "https://www.marketscreener.com/news/biontech-to-close-3-german-sites-after-unsuccessful-sale-efforts-ce785adcd18df22c", "source_link": "https://www.marketscreener.com/news/biontech-to-close-3-german-sites-after-unsuccessful-sale-efforts-ce785adcd18df22c", "source_link_is_lookup": false, "source_name": "marketscreener.com", "published_at": "2026-09-28T16:23:36", "published_display": "28 Sep 2026 16:23", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["marketscreener.com"], "source_kind": "publisher", "story_key": "24e906ed27c6f26aad76221ded4ccdeebab74ae19a074b865d9d7dc681e8c353", "target_scope": "BioNTech to Close 3 German Sites After Unsuccessful Sale Efforts BioNTech announced it will close three German sites after failing to sell them. but The company, known for its COVID-19 vaccine, has been restructuring and adjusting its operations.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": 0.4088, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001064, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 1.5, "age_days": 12.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences", "Mergers And Acquisitions"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech to close 3 German plants", "summary": "BioNTech announced its decision to close three manufacturing plants in Germany. This move is part of the company's strategic adjustments. Further details regarding the reasons for closure and the impact are expected.", "url": "https://breakingthenews.net/Article/BioNTech-to-close-3-German-plants/67188203", "source_link": "https://breakingthenews.net/Article/BioNTech-to-close-3-German-plants/67188203", "source_link_is_lookup": false, "source_name": "Breakingthenews.net", "published_at": "2026-09-28T12:23:36", "published_display": "28 Sep 2026 12:23", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Breakingthenews.net"], "source_kind": "publisher", "story_key": "52e467454f2037a7ee8c0677af765200ea50cd27e2a3b4314d17f59fddde64a2", "target_scope": "BioNTech to close 3 German plants BioNTech announced its decision to close three manufacturing plants in Germany.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": 0.4341, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001004, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 1.4, "age_days": 12.3, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Life Sciences", "Manufacturing"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech SE stock carries a USD 127.44 consensus target after Q2 miss", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNenJxaEV3bjNMZXdLSzRZaTBIVFJydF9OWFNrWVM0TjNYMi14M1VLTjFiTldzdW1PdnRfVkw0YkdaQVJ6RkRzWmJtY2hhUUZjcUI0ajF3NlJabU5yRDhRNWFVelMtVVRKQWZXYmVpTTJnN09RbkRGZnRLOHl5S0NTeDJwVFZnTlRmOW9mUDRxVnNZVEZIVDR0N3BVR095c3pKMUdkNUVxUkVlSW1LVGVTMGdlMmEzS01CeVgzUW9GX0V0YkdtdDBtc2lrcW8?oc=5", "source_link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNenJxaEV3bjNMZXdLSzRZaTBIVFJydF9OWFNrWVM0TjNYMi14M1VLTjFiTldzdW1PdnRfVkw0YkdaQVJ6RkRzWmJtY2hhUUZjcUI0ajF3NlJabU5yRDhRNWFVelMtVVRKQWZXYmVpTTJnN09RbkRGZnRLOHl5S0NTeDJwVFZnTlRmOW9mUDRxVnNZVEZIVDR0N3BVR095c3pKMUdkNUVxUkVlSW1LVGVTMGdlMmEzS01CeVgzUW9GX0V0YkdtdDBtc2lrcW8?oc=5", "source_link_is_lookup": false, "source_name": "AD HOC NEWS", "published_at": "2026-09-28T11:06:11+00:00", "published_display": "28 Sep 2026 11:06", "provider": "archive", "providers": ["archive", "google_news"], "provider_symbol": "", "provider_symbols": ["BNTX.ARCHIVE"], "target_provider_symbol": "BNTX.ARCHIVE", "cross_listing": false, "source_names": ["AD HOC NEWS"], "source_kind": "publisher", "story_key": "de2417405b5bcbc1adefaae128a16d0350cf46b725570364eb0fa432ffeb6afa", "target_scope": "BioNTech SE stock carries a USD 127.44 consensus target after Q2 miss", "durable_archive": true, "archive_provider": "google_news", "sentiment_origin": "target_heuristic", "model_confidence": 0.521, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 43, "tone_signals": ["Negative financial language"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.005916, "evidence_share": 1.8, "evidence_share_display": "1.8", "freshness_pct": 5.7, "age_days": 12.4, "influence_label": "Low", "evidence_strength": 30, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": true}, {"title": "Moderna vs. BioNTech: Which mRNA Cancer Stock Has More Upside?", "summary": "This article compares Moderna (MRNA) and BioNTech (BNTX) as investments in the mRNA cancer stock sector. It evaluates Moderna's clinical lead in cancer results against BioNTech's financial flexibility and broader oncology pipeline. The piece aims to determine which company offers a more attractive long-term setup for investors.", "url": "https://www.fool.com/investing/2026/09/28/moderna-vs-biontech-which-mrna-cancer-stock-has-mo", "source_link": "https://www.fool.com/investing/2026/09/28/moderna-vs-biontech-which-mrna-cancer-stock-has-mo", "source_link_is_lookup": false, "source_name": "The Motley Fool", "published_at": "2026-09-28T10:42:00", "published_display": "28 Sep 2026 10:42", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE", "MRNA", "NFLX", "NVDA"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["The Globe and Mail", "The Motley Fool"], "source_kind": "publisher", "story_key": "e9e7a1eaded358a97210f5e357e6d83901301260c487aa153dcbb1f09899d1e8", "target_scope": "BioNTech: Which mRNA Cancer Stock Has More Upside? This article compares Moderna (MRNA) and BioNTech (BNTX) as investments in the mRNA cancer stock sector. but It evaluates Moderna's clinical lead in cancer results against BioNTech's financial flexibility and broader oncology pipeline.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.521, "provider_directional_mass": 0.0389, "relevance_score": 1.0, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.028299, "evidence_share": 8.6, "evidence_share_display": "8.6", "freshness_pct": 18.0, "age_days": 12.4, "influence_label": "Low", "evidence_strength": 33, "duplicate_count": 2, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "How New Lung Cancer Data And Updated COVID Shot At BioNTech (BNTX) Has Changed Its Investment Story", "summary": "BioNTech's investment narrative is shifting due to new lung cancer data and an updated COVID-19 vaccine. The investigational CTLA\u20114 antibody gotistobart nearly doubled median overall survival in a Phase 3 lung cancer trial, boosting BioNTech's oncology pipeline. While COVID-19 vaccine revenue provides short-term cash flow, the company is heavily investing in oncology to secure long-term profitability, despite risks of prolonged losses and delayed approvals.", "url": "https://finance.yahoo.com/healthcare/articles/lung-cancer-data-updated-covid-011057743.html", "source_link": "https://finance.yahoo.com/healthcare/articles/lung-cancer-data-updated-covid-011057743.html", "source_link_is_lookup": false, "source_name": "Simply Wall St.", "published_at": "2026-09-27T01:10:57+00:00", "published_display": "27 Sep 2026 01:10", "provider": "yfinance", "providers": ["alphavantage", "archive", "eodhd", "yfinance"], "provider_symbol": "B1NT34.SA", "provider_symbols": ["0512.HK", "BNTX", "BNTX.ARCHIVE", "BNTX.US"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Market source", "Simply Wall St.", "finance.yahoo.com"], "source_kind": "publisher", "story_key": "57457a4a81f43a66430d35bb0009c4799c3076fee9dca3755a7d00090dbf7dbb", "target_scope": "How New Lung Cancer Data And Updated COVID Shot At BioNTech (BNTX) Has Changed Its Investment Story BioNTech's investment narrative is shifting due to new lung cancer data and an updated COVID-19 vaccine. The investigational CTLA\u20114 antibody gotistobart nearly doubled median overall survival in a Phase 3 lung cancer trial, boosting BioNTech's oncology pipeline.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 1.0, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.024858, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 25.5, "age_days": 13.8, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 3, "topics": ["Biotech", "Earnings", "Financial Markets", "Healthcare", "Life Sciences", "Oncology"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech SE (22UA.F) Stock Price, News, Quote & History", "summary": "This Yahoo Finance page provides comprehensive financial information for BioNTech SE (22UA.F), including its current stock price, historical data, and key statistics. It details the company's overview as a biotechnology firm involved in developing immunotherapies, particularly its SARS-CoV-2 vaccine and various oncology drugs in clinical trials. The article also presents performance metrics, earnings trends, and valuation measures for BioNTech SE.", "url": "https://ca.finance.yahoo.com/quote/22UA.F", "source_link": "https://ca.finance.yahoo.com/quote/22UA.F", "source_link_is_lookup": false, "source_name": "Yahoo! Finance Canada", "published_at": "2026-09-25T10:53:55", "published_display": "25 Sep 2026 10:53", "provider": "alphavantage", "providers": ["alphavantage", "archive", "google_news"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE", "MRNA"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Yahoo! Finance Canada"], "source_kind": "publisher", "story_key": "31186d91a21b53f537ae1120c00731e76e406f8911f1ac84f111a7fb0160125c", "target_scope": "BioNTech SE (22UA.F) Stock Price, News, Quote & History This Yahoo Finance page provides comprehensive financial information for BioNTech SE (22UA.F), including its current stock price, historical data, and key statistics. but It details the company's overview as a biotechnology firm involved in developing immunotherapies, particularly its SARS-CoV-2 vaccine and various oncology drugs in clinical trials. The article also presents performance metrics, earnings trends, and valuation measures for BioNTech SE.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": 0.1069, "relevance_score": 1.0, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.010037, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 11.9, "age_days": 15.4, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Form 4 BioNTech SE For: 25 September By Investing.com", "summary": "This article announces the filing of a Form 4 for BioNTech SE on September 25. It is a brief financial news update indicating a regulatory filing concerning the company. The article also lists BioNTech's stock performance for the day.", "url": "https://ca.investing.com/news/stock-market-news/form-4-biontech-se-for-25-september-93CH-4853124", "source_link": "https://ca.investing.com/news/stock-market-news/form-4-biontech-se-for-25-september-93CH-4853124", "source_link_is_lookup": false, "source_name": "Investing.com Canada", "published_at": "2026-09-25T08:53:56", "published_display": "25 Sep 2026 08:53", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Investing.com Canada", "Investing.com Nigeria"], "source_kind": "publisher", "story_key": "c90d0c3850f22b56bb3aeeb7b5464b56732a88166dec775336dd610c3b413e93", "target_scope": "Form 4 BioNTech SE For: 25 September By Investing.com This article announces the filing of a Form 4 for BioNTech SE on September 25. but It is a brief financial news update indicating a regulatory filing concerning the company. The article also lists BioNTech's stock performance for the day.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": 0.0124, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.037527, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 21.6, "age_days": 15.5, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?", "summary": "Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026\u20132027 COVID-19 vaccine formula, COMIRNATY XFG. The updated formula targets the XFG variant and is authorized for adults aged 65 and older, as well as individuals aged 5 to 64 with high-risk underlying conditions. Based on clinical, real-world, and manufacturing data demonstrating strong immune responses against circulating strains, the approval aligns with FDA strain guidance for fall 2026. You May Also Want to Look At: Pfizer (", "url": "https://finance.yahoo.com/healthcare/articles/could-vaccine-formula-xfg-pfizer-202715476.html", "source_link": "https://finance.yahoo.com/healthcare/articles/could-vaccine-formula-xfg-pfizer-202715476.html", "source_link_is_lookup": false, "source_name": "Insider Monkey", "published_at": "2026-09-24T20:27:15+00:00", "published_display": "24 Sep 2026 20:27", "provider": "yfinance", "providers": ["archive", "eodhd", "google_news", "yfinance"], "provider_symbol": "BNTX.US", "provider_symbols": ["AZN.US", "BNTX", "BNTX.ARCHIVE", "BNTX.US", "PFE", "PFE.DU", "PFE.MU", "PFE.US", "VALN", "VALN.US"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Insider Monkey", "Market source", "finance.yahoo.com"], "source_kind": "publisher", "story_key": "f717c65d807f1e319e14272b7721a50137bc29647753a9986546d15f518e96e0", "target_scope": "Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost? Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026\u20132027 COVID-19 vaccine formula, COMIRNATY XFG.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.54, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 52, "tone_signals": ["Contract or approval won"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.009978, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 10.9, "age_days": 16.0, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 3, "topics": ["Balance Sheet", "Covid 19 Vaccine", "Fda Approval", "Pharma"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech (BNTX) CEO Ugur Sahin sold shares on two days under a trading plan set in June.", "summary": "BioNTech CEO Ugur Sahin sold 69,000 ordinary shares of BNTX on September 23 and 24, 2026, under a Rule 10b5-1 trading plan established on June 3, 2026. The sales totaled approximately $6.84 million, with shares sold at prices of $99.4027 and $98.9913, respectively. Sahin still indirectly holds over 39 million shares through Medine GmbH, where he is the sole shareholder.", "url": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-4d1305766bd5.html", "source_link": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-4d1305766bd5.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-09-24T20:53:56", "published_display": "24 Sep 2026 20:53", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Stock Titan"], "source_kind": "publisher", "story_key": "5d5dea3ac1934f711da22580eb681d739c0302ae4f502fbce0d01c29992f0aee", "target_scope": "BioNTech (BNTX) CEO Ugur Sahin sold shares on two days under a trading plan set in June. BioNTech CEO Ugur Sahin sold 69,000 ordinary shares of BNTX on September 23 and 24, 2026, under a Rule 10b5-1 trading plan established on June 3, 2026.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.694, "provider_directional_mass": 0.2872, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 40, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000557, "evidence_share": 0.2, "evidence_share_display": "0.2", "freshness_pct": 0.4, "age_days": 16.0, "influence_label": "Low", "evidence_strength": 34, "duplicate_count": 1, "topics": ["Earnings", "Finance", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BNTX Stock Price and Chart \u2014 NASDAQ:BNTX", "summary": "This article provides an overview of BioNTech SE (NASDAQ: BNTX) stock, including its price performance, key facts, and financial statistics. Recent developments include potential job cuts and site closures, ongoing patent litigation with Bayer CropScience, and a revised price target from Citi. The company continues to be active in mRNA technology beyond COVID-19, with a focus on oncology and other therapies.", "url": "https://www.tradingview.com/symbols/NASDAQ-BNTX", "source_link": "https://www.tradingview.com/symbols/NASDAQ-BNTX", "source_link_is_lookup": false, "source_name": "TradingView", "published_at": "2026-09-24T13:00:44", "published_display": "24 Sep 2026 13:00", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE", "PFE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["TradingView"], "source_kind": "publisher", "story_key": "03755ff83acd1304d37e413ef19425dc6b0eadcab71969c21d9a7fd5c08c0d97", "target_scope": "BNTX Stock Price and Chart NASDAQ:BNTX This article provides an overview of BioNTech SE (NASDAQ: BNTX) stock, including its price performance, key facts, and financial statistics.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": 0.2094, "relevance_score": 1.0, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000194, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.4, "age_days": 16.3, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Canaccord Genuity Reaffirms Their Buy Rating on BioNTech SE (BNTX)", "summary": "Canaccord Genuity analyst John Newman maintained a Buy rating on BioNTech SE (BNTX) with a price target of $136.00. This rating aligns with Morgan Stanley's Buy rating, though BMO Capital has a Hold rating on the stock. BioNTech SE reported a quarterly revenue of $105.6 million and a GAAP net loss of $820.8 million for the quarter ending June 30.", "url": "https://www.theglobeandmail.com/investing/markets/stocks/BNTX-Q/pressreleases/4774321/canaccord-genuity-reaffirms-their-buy-rating-on-biontech-se-bntx", "source_link": "https://www.theglobeandmail.com/investing/markets/stocks/BNTX-Q/pressreleases/4774321/canaccord-genuity-reaffirms-their-buy-rating-on-biontech-se-bntx", "source_link_is_lookup": false, "source_name": "The Globe and Mail", "published_at": "2026-09-24T12:53:56", "published_display": "24 Sep 2026 12:53", "provider": "alphavantage", "providers": ["alphavantage", "archive", "google_news"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["The Globe and Mail"], "source_kind": "publisher", "story_key": "5276136aaed393cdc98382ef9714cca9845b1dd39ac31d20116ced295f80ffc2", "target_scope": "Canaccord Genuity Reaffirms Their Buy Rating on BioNTech SE (BNTX) Canaccord Genuity analyst John Newman maintained a Buy rating on BioNTech SE (BNTX) with a price target of $136.00. BioNTech SE reported a quarterly revenue of $105.6 million and a GAAP net loss of $820.8 million for the quarter ending June 30.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.732, "provider_directional_mass": 0.3296, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.083, "sentiment": "positive", "sentiment_pct": 71, "tone_signals": ["Buy Rating"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.005266, "evidence_share": 1.6, "evidence_share_display": "1.6", "freshness_pct": 2.3, "age_days": 16.3, "influence_label": "Medium", "evidence_strength": 45, "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech stock rises 2.0 percent after the close", "summary": "BioNTech stock rose 2.0 percent after the close on September 22, 2026, reaching USD 100.42 in Tuesday morning trading on the Nasdaq. This increase followed a prior Nasdaq close of USD 97.71 on September 21, and the company had gained 5 percent year-to-date. The outlook also noted that BMO had recently lowered its 12-month target for BioNTech shares from USD 128 to USD 105.", "url": "https://www.ad-hoc-news.de/boerse/news/nebenwerte/biontech-stock-rises-2-0-percent-after-the-close/70159583", "source_link": "https://www.ad-hoc-news.de/boerse/news/nebenwerte/biontech-stock-rises-2-0-percent-after-the-close/70159583", "source_link_is_lookup": false, "source_name": "AD HOC NEWS", "published_at": "2026-09-22T22:30:00", "published_display": "22 Sep 2026 22:30", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["AD HOC NEWS"], "source_kind": "publisher", "story_key": "0b1dc7b45d52f9ee9332a286b59ca3891d7c6962f1abefc9f249a984560bbc2a", "target_scope": "BioNTech stock rises 2.0 percent after the close BioNTech stock rose 2.0 percent after the close on September 22, 2026, reaching USD 100.42 in Tuesday morning trading on the Nasdaq. The outlook also noted that BMO had recently lowered its 12-month target for BioNTech shares from USD 128 to USD 105.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.522, "provider_directional_mass": 0.2782, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.195, "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.030742, "evidence_share": 9.3, "evidence_share_display": "9.3", "freshness_pct": 17.0, "age_days": 17.9, "influence_label": "Medium", "evidence_strength": 36, "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech (NASDAQ: BNTX) CEO sells 79K shares, still holds 39.2M", "summary": "BioNTech CEO Ugur Sahin sold 79,000 Ordinary Shares of BNTX on September 21-22, 2026, through a Rule 10b5-1 trading plan. Despite these sales, Sahin retains a significant indirect stake of 39,218,111 Ordinary Shares held via Medine GmbH, for which he is the sole shareholder. The transactions were executed at prices of $100.7182 and $97.8097 per share.", "url": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-bce53a94a80e.html", "source_link": "https://www.stocktitan.net/sec-filings/BNTX/form-4-bio-n-tech-se-insider-trading-activity-bce53a94a80e.html", "source_link_is_lookup": false, "source_name": "Stock Titan", "published_at": "2026-09-22T20:54:37", "published_display": "22 Sep 2026 20:54", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Stock Titan"], "source_kind": "publisher", "story_key": "e0d6ce20cc02a50c2b06645ca3cdfe4eef753a6c5ba5628ceb152076ad9166b1", "target_scope": "BioNTech (NASDAQ: BNTX) CEO sells 79K shares, still holds 39.2M BioNTech CEO Ugur Sahin sold 79,000 Ordinary Shares of BNTX on September 21-22, 2026, through a Rule 10b5-1 trading plan.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.694, "provider_directional_mass": 0.2139, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "negative", "sentiment_pct": 40, "tone_signals": ["Institutional or insider selling"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.000279, "evidence_share": 0.1, "evidence_share_display": "<0.1", "freshness_pct": 0.2, "age_days": 18.0, "influence_label": "Low", "evidence_strength": 34, "duplicate_count": 1, "topics": ["Earnings", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech price tries to regain footing - Forecast today - 23-09-2026", "summary": "BioNTech SE (BNTX) showed an advance in recent intraday trading, finding support at its 50-day Simple Moving Average and exhibiting fresh bullish signals from momentum indicators in oversold territory. The stock is maintaining a short-term uptrend, following an ascending trendline. The outlook remains bullish as long as support at $95.30 holds, with an expected target of $105.50 for its first resistance level.", "url": "https://www.economies.com/stocks/united-states-analysis/biontech-price-tries-to-regain-footing---forecast-today---23-09-2026-130438", "source_link": "https://www.economies.com/stocks/united-states-analysis/biontech-price-tries-to-regain-footing---forecast-today---23-09-2026-130438", "source_link_is_lookup": false, "source_name": "Economies.com", "published_at": "2026-09-22T12:32:00", "published_display": "22 Sep 2026 12:32", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Economies.com"], "source_kind": "publisher", "story_key": "4d40225f87d12ebafe3104913c2b4cc4e7164d1912516ed149bda858349f83a4", "target_scope": "BioNTech price tries to regain footing - Forecast today - 23-09-2026 BioNTech SE (BNTX) showed an advance in recent intraday trading, finding support at its 50-day Simple Moving Average and exhibiting fresh bullish signals from momentum indicators in oversold territory.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.51, "provider_directional_mass": 0.4441, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Positive financial language"], "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.023959, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 16.3, "age_days": 18.3, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?", "summary": "BMO Capital Markets downgraded BioNTech (BNTX) from \"outperform\" to \"market perform\" and lowered its price target due to waning COVID-19 vaccine demand and a setback in its colorectal cancer vaccine trial. Despite these challenges and a revised revenue forecast, the article argues that BioNTech's extensive oncology pipeline, with over 25 Phase 2 and Phase 3 clinical studies, is being underestimated by Wall Street. The company also holds significant cash reserves, suggesting that investors can acquire a robust pipeline at a perceived value.", "url": "https://www.fool.com/investing/2026/09/22/biontech-stock-recently-got-downgraded-but-is-wall", "source_link": "https://www.fool.com/investing/2026/09/22/biontech-stock-recently-got-downgraded-but-is-wall", "source_link_is_lookup": false, "source_name": "The Motley Fool", "published_at": "2026-09-22T09:54:37", "published_display": "22 Sep 2026 09:54", "provider": "alphavantage", "providers": ["alphavantage", "archive", "eodhd"], "provider_symbol": "BNTX.US", "provider_symbols": ["BMO.US", "BNTX", "BNTX.ARCHIVE", "BNTX.US", "MRK", "MRK.US", "MRNA", "MRNA.US", "NVDA.US"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["The Motley Fool", "finance.yahoo.com"], "source_kind": "publisher", "story_key": "7fb511e8ed300ba26b0f7a59b7ccd4263c306d63780185e9e6d99c452c9cfcb5", "target_scope": "BioNTech Stock Recently Got Downgraded. BMO Capital Markets downgraded BioNTech (BNTX) from \"outperform\" to \"market perform\" and lowered its price target due to waning COVID-19 vaccine demand and a setback in its colorectal cancer vaccine trial. Despite these challenges and a revised revenue forecast, the article argues that BioNTech's extensive oncology pipeline, with over 25 Phase 2 and Phase 3 clinical studies, is being underestimated by Wall Street. but The company also holds significant cash reserves, suggesting that investors can acquire a robust pipeline at a perceived value.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.5760000000000001, "provider_directional_mass": 0.2913, "relevance_score": 1.0, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.195, "sentiment": "neutral", "sentiment_pct": 46, "tone_signals": ["Analyst downgrade"], "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001825, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 1.4, "age_days": 18.4, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Biotech", "Cancer", "Clinical Trials", "Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech SE (BNTX) Stock Analysis: Navigating a 23% Potential Upside Amidst Challenging Financials", "summary": "BioNTech SE (BNTX), a German biotechnology firm known for its mRNA vaccine, presents a potential 23% upside despite current financial challenges including a negative P/E ratio and revenue growth. The company is strategically diversifying its pipeline into oncology and other infectious diseases. While financial metrics suggest caution, analyst ratings remain optimistic, highlighting a balance between innovative potential and financial health for investors.", "url": "https://www.directorstalkinterviews.com/biontech-se-bntx-stock-analysis-navigating-a-23-potential-upside-amidst-challenging-financials/4121263202", "source_link": "https://www.directorstalkinterviews.com/biontech-se-bntx-stock-analysis-navigating-a-23-potential-upside-amidst-challenging-financials/4121263202", "source_link_is_lookup": false, "source_name": "DirectorsTalk Interviews", "published_at": "2026-09-22T05:54:37", "published_display": "22 Sep 2026 05:54", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["DirectorsTalk Interviews"], "source_kind": "publisher", "story_key": "07f0d0c7dc7490455045079e676127384e00ae2c1d37185278d5e19eecb69159", "target_scope": "BioNTech SE (BNTX) Stock Analysis: Navigating a 23% Potential Upside Amidst Challenging Financials BioNTech SE (BNTX), a German biotechnology firm known for its mRNA vaccine, presents a potential 23% upside despite current financial challenges including a negative P/E ratio and revenue growth. but The company is strategically diversifying its pipeline into oncology and other infectious diseases.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.627, "provider_directional_mass": 0.1302, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.186, "sentiment": "positive", "sentiment_pct": 61, "tone_signals": ["Operating growth"], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.015193, "evidence_share": 4.6, "evidence_share_display": "4.6", "freshness_pct": 7.6, "age_days": 18.6, "influence_label": "Medium", "evidence_strength": 38, "duplicate_count": 1, "topics": ["Earnings", "Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher", "summary": "Quick Read Moderna surged 9% to $168 after its Phase 3 melanoma vaccine study earned the ESMO congress's highest-profile Presidential Symposium slot on October 24. Merck gained just 1% and BioNTech 2%, signaling the market views this as a Moderna-specific re-rating, not a broad mRNA oncology validation. No new efficacy data was released Monday; the Presidential Symposium slot itself is the signal, as organizers reserve it for practice-changing datasets. Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Merck didn't make the cut. Ente", "url": "https://finance.yahoo.com/healthcare/articles/moderna-surges-9-phase-3-154555747.html", "source_link": "https://finance.yahoo.com/healthcare/articles/moderna-surges-9-phase-3-154555747.html", "source_link_is_lookup": false, "source_name": "24/7 Wall St.", "published_at": "2026-09-21T15:45:55+00:00", "published_display": "21 Sep 2026 15:45", "provider": "yfinance", "providers": ["archive", "eodhd", "yfinance"], "provider_symbol": "BNTX.US", "provider_symbols": ["BNTX", "BNTX.ARCHIVE", "BNTX.US", "IBB", "IBB.US", "MRK", "MRK.US", "MRNA", "MRNA.US", "SPY", "SPY.US"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["24/7 Wall St.", "finance.yahoo.com"], "source_kind": "publisher", "story_key": "3667a0e95e65acf8d7c42f836c941a28b9566fc10cd37ab168f622449219c2f8", "target_scope": "Merck and BioNTech Edge Higher Merck gained just 1% and BioNTech 2%, signaling the market views this as a Moderna-specific re-rating, not a broad mRNA oncology validation.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 6.1e-05, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.1, "age_days": 19.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Biotech", "Clinical Trials", "Moderna", "Oncology", "Price Target", "Split"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech SE - American Depositary Shares (NQ: BNTX)", "summary": "This article provides a brief overview of BioNTech SE (BNTX) stock performance, showing a price of 100.87 with a 2.87 (+2.93%) increase, as of 4:00 PM EDT, Sep 22, 2026. It lists various sections for investors to find more information, such as detailed quotes, charting, historical prices, news, and research reports. The content primarily focuses on providing a framework for accessing financial data related to BioNTech SE.", "url": "https://markets.chroniclejournal.com/observerreporter/quote/news?Symbol=NQ%3ABNTX&CurrentPage=63", "source_link": "https://markets.chroniclejournal.com/observerreporter/quote/news?Symbol=NQ%3ABNTX&CurrentPage=63", "source_link_is_lookup": false, "source_name": "The Chronicle-Journal", "published_at": "2026-09-19T05:54:37", "published_display": "19 Sep 2026 05:54", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["The Chronicle-Journal"], "source_kind": "publisher", "story_key": "b6880900ae501dcad3268f60b238ff23fffba3b5530e701030a274d6762ad80c", "target_scope": "BioNTech SE - American Depositary Shares (NQ: BNTX) This article provides a brief overview of BioNTech SE (BNTX) stock performance, showing a price of 100.87 with a 2.87 (+2.93%) increase, as of 4:00 PM EDT, Sep 22, 2026. but It lists various sections for investors to find more information, such as detailed quotes, charting, historical prices, news, and research reports. The content primarily focuses on providing a framework for accessing financial data related to BioNTech SE.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": 0.0242, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 4e-05, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.1, "age_days": 21.6, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher", "summary": "Quick Read Moderna surged 5% to $152.83, extending a stunning 137% one-month run fueled solely by its Phase 2b melanoma vaccine data showing a 49% reduction in recurrence risk. BioNTech edged up just 1% despite running a rival mRNA cancer vaccine program, signaling markets are backing Moderna's specific asset, not the broader platform. A Phase 3 adjuvant melanoma interim analysis expected in late 2026 is the next swing factor, with Madrid's October oncology congress as the nearest public data window. Read More: Avoid these 13 retirement mistakes before they derail your future (sponsor) Cancer ", "url": "https://finance.yahoo.com/healthcare/articles/moderna-climbs-6-cancer-vaccine-135031898.html", "source_link": "https://finance.yahoo.com/healthcare/articles/moderna-climbs-6-cancer-vaccine-135031898.html", "source_link_is_lookup": false, "source_name": "24/7 Wall St.", "published_at": "2026-09-17T13:50:31+00:00", "published_display": "17 Sep 2026 13:50", "provider": "yfinance", "providers": ["archive", "eodhd", "yfinance"], "provider_symbol": "BNTX.US", "provider_symbols": ["BNTX", "BNTX.ARCHIVE", "BNTX.US", "GSPC.INDX", "IBB", "IBB.US", "MRK", "MRK.US", "MRNA", "MRNA.US", "NVAX", "NVAX.US", "SPY", "SPY.US", "^GSPC"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["24/7 Wall St.", "finance.yahoo.com"], "source_kind": "publisher", "story_key": "6c27d99475137e6815f61918453c78d54b9448aa73f98592dfac55d3597b31b8", "target_scope": "BioNTech and Novavax Edge Higher BioNTech edged up just 1% despite running a rival mRNA cancer vaccine program, signaling markets are backing Moderna's specific asset, not the broader platform.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 1.5e-05, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.0, "age_days": 23.3, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Biotech", "Cancer Vaccine", "Clinical Trials", "Earnings", "Guidance", "Revenue Growth"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Is BioNTech (BNTX) Too Pricey for Its Current Sales Base?", "summary": "BioNTech has been in focus again after fresh clinical trial results, yet the long slide in the share price keeps pulling attention back to a simple question about what investors are paying for its sales. With the stock well below where it traded several years ago, the issue is whether today's valuation rests on a solid revenue base or on expectations that are hard to pin down. Over the past 5 years the share price has fallen 71.5%, which puts the spotlight firmly on whether the current valuation can still be explained by the company's sales profile. News that gotistobart nearly doubled median ", "url": "https://finance.yahoo.com/healthcare/articles/biontech-bntx-too-pricey-current-221344796.html", "source_link": "https://finance.yahoo.com/healthcare/articles/biontech-bntx-too-pricey-current-221344796.html", "source_link_is_lookup": false, "source_name": "Simply Wall St.", "published_at": "2026-09-16T22:13:44+00:00", "published_display": "16 Sep 2026 22:13", "provider": "yfinance", "providers": ["archive", "eodhd", "yfinance"], "provider_symbol": "BNTX.US", "provider_symbols": ["B1NT34.SA", "BNTX", "BNTX.ARCHIVE", "BNTX.US"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Simply Wall St.", "finance.yahoo.com"], "source_kind": "publisher", "story_key": "4a789e06a69eaaed1d284049b949b836042068803745a2d3320d7bb3e74e3ae1", "target_scope": "Is BioNTech (BNTX) Too Pricey for Its Current Sales Base? BioNTech has been in focus again after fresh clinical trial results, yet the long slide in the share price keeps pulling attention back to a simple question about what investors are paying for its sales.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.88388, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.002845, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 3.6, "age_days": 23.9, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Biotech", "Clinical Trials", "Oncology", "Share Price", "Split", "Valuation"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "BioNTech (BNTX) Posts Strong Lung Cancer Data, Is It A Bargain?", "summary": "BioNTech (NasdaqGS:BNTX) moved after fresh clinical news, as investors reacted to detailed Phase 3 data showing its investigational lung cancer therapy gotistobart nearly doubled median overall survival compared with standard chemotherapy. At around US$96.69 per share, BioNTech has seen a 30 day share price return of 3.87% and a 90 day share price return of 4.85%, while the 1 year total shareholder return declined 2.59% and the 5 year total shareholder return fell 71.40%. This suggests that short term momentum has picked up even as long term holders have experienced heavy losses. Scan beyond B", "url": "https://finance.yahoo.com/healthcare/articles/biontech-bntx-posts-strong-lung-190825692.html", "source_link": "https://finance.yahoo.com/healthcare/articles/biontech-bntx-posts-strong-lung-190825692.html", "source_link_is_lookup": false, "source_name": "Simply Wall St.", "published_at": "2026-09-16T19:08:25+00:00", "published_display": "16 Sep 2026 19:08", "provider": "yfinance", "providers": ["archive", "eodhd", "yfinance"], "provider_symbol": "BNTX.US", "provider_symbols": ["22UA.F", "B1NT34.SA", "BNTX", "BNTX.ARCHIVE", "BNTX.US"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Simply Wall St.", "finance.yahoo.com"], "source_kind": "publisher", "story_key": "9df94c58bdf34c54bacac60e880654401617929006159acd1fc4e7d0e094a2d3", "target_scope": "BioNTech (BNTX) Posts Strong Lung Cancer Data, Is It A Bargain? BioNTech (NasdaqGS:BNTX) moved after fresh clinical news, as investors reacted to detailed Phase 3 data showing its investigational lung cancer therapy gotistobart nearly doubled median overall survival compared with standard chemotherapy. At around US$96.69 per share, BioNTech has seen a 30 day share price return of 3.87% and a 90 day share price return of 4.85%,", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.521, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 57, "tone_signals": ["Positive financial language"], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.010519, "evidence_share": 3.2, "evidence_share_display": "3.2", "freshness_pct": 9.3, "age_days": 24.0, "influence_label": "Low", "evidence_strength": 30, "duplicate_count": 2, "topics": ["Clinical Trials", "Earnings", "M A", "Oncology", "Pharma", "Revenue Growth"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech\u2019s Lung Cancer Drug Shows Signs of a Major Breakthrough", "summary": "BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need. The result builds on earlier Stage 1 data, where gotistobart red", "url": "https://finance.yahoo.com/healthcare/articles/biontech-lung-cancer-drug-shows-143753280.html", "source_link": "https://finance.yahoo.com/healthcare/articles/biontech-lung-cancer-drug-shows-143753280.html", "source_link_is_lookup": false, "source_name": "Insider Monkey", "published_at": "2026-09-15T14:37:53+00:00", "published_display": "15 Sep 2026 14:37", "provider": "yfinance", "providers": ["archive", "eodhd", "yfinance"], "provider_symbol": "BNTX.US", "provider_symbols": ["ASML.US", "BNTX", "BNTX.ARCHIVE", "BNTX.US"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Insider Monkey", "finance.yahoo.com"], "source_kind": "publisher", "story_key": "402cecdfa11175da0a40cef8b95c0acac58a47228d3d28e84a11300e9302822e", "target_scope": "BioNTech\u2019s Lung Cancer Drug Shows Signs of a Major Breakthrough BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.006863, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 8.2, "age_days": 25.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Balance Sheet", "Biotech", "Clinical Trials", "Lung Cancer", "Oncology", "Pharma"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech SE (BNTX) Gets a Buy from Morgan Stanley", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQaElWamdQcnVHVVRKUnZYeVRFOVRaeE4yTDFYdHpWYTdrQTdVUDEtOGdhV2JpWGg3V0xSNFZPSklWVzgtU0JKWFZMajBLME4zTFVBVEVoTUhkTDU2ajdXX0FoVDQwMlVBcTBiSFB6ODRJT2xVQVVERHdQbFE3UDl0TGN3a0s5VzRvbkJFZHFOUkRnVVk0TnBlOTk0YWc4VWNGVlBFbl9aWTdLN2lPYVBPdWJ2dktibFQ2dVlza3hvajcwOEZaTUwxTWdSNHk?oc=5", "source_link": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQaElWamdQcnVHVVRKUnZYeVRFOVRaeE4yTDFYdHpWYTdrQTdVUDEtOGdhV2JpWGg3V0xSNFZPSklWVzgtU0JKWFZMajBLME4zTFVBVEVoTUhkTDU2ajdXX0FoVDQwMlVBcTBiSFB6ODRJT2xVQVVERHdQbFE3UDl0TGN3a0s5VzRvbkJFZHFOUkRnVVk0TnBlOTk0YWc4VWNGVlBFbl9aWTdLN2lPYVBPdWJ2dktibFQ2dVlza3hvajcwOEZaTUwxTWdSNHk?oc=5", "source_link_is_lookup": false, "source_name": "The Globe and Mail", "published_at": "2026-09-15T07:00:00+00:00", "published_display": "15 Sep 2026 07:00", "provider": "google_news", "providers": ["archive", "google_news"], "provider_symbol": "", "provider_symbols": ["BNTX.ARCHIVE"], "target_provider_symbol": "BNTX.ARCHIVE", "cross_listing": false, "source_names": ["The Globe and Mail", "theglobeandmail.com"], "source_kind": "publisher", "story_key": "efe09c05062fb75fcdbc84323f9133eef75113694c6d674b48fa4cd6b1849625", "target_scope": "BioNTech SE (BNTX) Gets a Buy from Morgan Stanley", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 9e-06, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.0, "age_days": 25.5, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Why Is BioNTech Stock Gaining Monday?", "summary": "On Monday, BioNTech SE(NASDAQ:BNTX) and OncoC4 Inc. released the first median overall survival results from stage 1 of their global PRESERVE-003 Phase 3 trial. The data indicate their investigational therapy nearly doubled survival times compared to standard chemotherapy for a specific patient population. Following the announcement, the stock jumped nearly 2%. Evaluating Gotistobart for Lung Cancer The study investigates gotistobart (BNT316 or ONC-392) for metastatic squamous non-small cell lung cancer (NSCLC). It focuses on patients whose cancer advanced despite prior immunotherapy and chemot", "url": "https://finance.yahoo.com/healthcare/articles/why-biontech-stock-gaining-monday-143512744.html", "source_link": "https://finance.yahoo.com/healthcare/articles/why-biontech-stock-gaining-monday-143512744.html", "source_link_is_lookup": false, "source_name": "Benzinga", "published_at": "2026-09-14T14:35:12+00:00", "published_display": "14 Sep 2026 14:35", "provider": "archive", "providers": ["archive", "eodhd", "yfinance"], "provider_symbol": "BNTX.US", "provider_symbols": ["22UA.F", "B1NT34.SA", "BNTX", "BNTX.ARCHIVE", "BNTX.US", "FOMC.US"], "target_provider_symbol": "BNTX.ARCHIVE", "cross_listing": false, "source_names": ["Benzinga", "finance.yahoo.com"], "source_kind": "publisher", "story_key": "1d7ca43848d33ad588ea4b9cef736ebb05a8883c858cf86111a12a15e071a886", "target_scope": "Why Is BioNTech Stock Gaining Monday? On Monday, BioNTech SE(NASDAQ:BNTX) and OncoC4 Inc. released the first median overall survival results from stage 1 of their global PRESERVE-003 Phase 3 trial.", "durable_archive": false, "archive_provider": "archive", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.002231, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 2.6, "age_days": 26.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Biotech", "Clinical Trials", "Lung Cancer", "Pharma"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "BioNTech stock jumps on positive lung cancer trial data", "summary": "BioNTech's shares jumped after the company announced positive clinical trial data for its experimental lung cancer drug, gotistobart. The drug nearly doubled the median overall survival rate in patients with squamous non-small cell lung cancer compared to standard chemotherapy. This data comes from an ongoing Phase 3 trial and was presented at a major lung cancer conference.", "url": "https://m.investing.com/news/stock-market-news/biontech-stock-jumps-on-positive-lung-cancer-trial-data-93CH-4899652?ampMode=1", "source_link": "https://m.investing.com/news/stock-market-news/biontech-stock-jumps-on-positive-lung-cancer-trial-data-93CH-4899652?ampMode=1", "source_link_is_lookup": false, "source_name": "Investing.com", "published_at": "2026-09-14T12:37:06", "published_display": "14 Sep 2026 12:37", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Investing.com"], "source_kind": "publisher", "story_key": "f8fe6f80aebadfe21cdc5560ed7fde4c2bd02c8246e43ec01446fc8a6286e607", "target_scope": "BioNTech stock jumps on positive lung cancer trial data BioNTech's shares jumped after the company announced positive clinical trial data for its experimental lung cancer drug, gotistobart.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.754, "provider_directional_mass": 0.43, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "positive", "sentiment_pct": 71, "tone_signals": ["Positive market reaction"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 2.9e-05, "evidence_share": 0.0, "evidence_share_display": "<0.1", "freshness_pct": 0.0, "age_days": 26.3, "influence_label": "Medium", "evidence_strength": 45, "duplicate_count": 1, "topics": ["Financial Markets", "Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": true}, {"title": "BioNTech adds clinical weight to its oncology pivot at WCLC 2026", "summary": "BioNTech presented new clinical data at the World Conference on Lung Cancer (WCLC) in Seoul, bolstering its oncology strategy beyond its mRNA platform. The anti-CTLA-4 antibody gotistobart showed significant survival benefits in previously treated NSCLC, while the bispecific antibody pumitamig demonstrated encouraging signals across tumor types and in combination with an ADC. These developments highlight BioNTech's pivot towards a diverse, combination-driven oncology portfolio.", "url": "https://european-biotechnology.com/background/biontech-adds-clinical-weight-to-its-oncology-pivot-at-wclc-2026", "source_link": "https://european-biotechnology.com/background/biontech-adds-clinical-weight-to-its-oncology-pivot-at-wclc-2026", "source_link_is_lookup": false, "source_name": "European Biotechnology Magazine", "published_at": "2026-09-14T09:37:06", "published_display": "14 Sep 2026 09:37", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["European Biotechnology Magazine"], "source_kind": "publisher", "story_key": "df41abaf5a2a42b0f55e4234213929be30024797353ca2f219c75748139a74fb", "target_scope": "BioNTech adds clinical weight to its oncology pivot at WCLC 2026 BioNTech presented new clinical data at the World Conference on Lung Cancer (WCLC) in Seoul, bolstering its oncology strategy beyond its mRNA platform. These developments highlight BioNTech's pivot towards a diverse, combination-driven oncology portfolio.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": 0.0025, "relevance_score": 0.78, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 6e-06, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.0, "age_days": 26.4, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients", "summary": "BioNTech SE Gotistobart continues to show potential aschemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current standard of care treatments is less than one year1 Gotistobart demonstrated a median overall survival of 18.5 months compared to 10.0 months with standard-of-care chemotherapy in updated data from stage 1 of the PRESERVE-003 Phase 3 clinical trial, nearly doubling median survival in this patient population Findings are consistent with gotistobart's differentiated mechanism ", "url": "https://finance.yahoo.com/healthcare/articles/biontech-oncoc4-present-updated-data-080000169.html", "source_link": "https://finance.yahoo.com/healthcare/articles/biontech-oncoc4-present-updated-data-080000169.html", "source_link_is_lookup": false, "source_name": "GlobeNewswire", "published_at": "2026-09-14T08:00:00+00:00", "published_display": "14 Sep 2026 08:00", "provider": "yfinance", "providers": ["archive", "eodhd", "yfinance"], "provider_symbol": "B1NT34.SA", "provider_symbols": ["B1NT34.SA", "BNTX", "BNTX.ARCHIVE", "BNTX.US"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["GlobeNewswire", "finance.yahoo.com"], "source_kind": "press_release", "story_key": "10bcc3b4463c321bc8525e29eeeab68922db8a926b7a3ec093969d8a325b6605", "target_scope": "BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients BioNTech SE Gotistobart continues to show potential aschemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current standard of care treatments is less than one year1 Gotistobart demonstrated a median overall survival of 18.5 months compared to 10.0 months with standard-of-care chemotherapy in updated data from stage 1 of the PRESERVE-003 Phase 3 clinical trial, nearly doubling median survival in this patient population Findings are consistent with gotistobart's differentiated mechanism", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 5e-06, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.0, "age_days": 26.5, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Clinical Trials", "Immunotherapy", "Lung Cancer", "Pharma"], "evidence_basis": "archived_article", "score_included": true, "direction_included": false}, {"title": "BioNTech says lung cancer drug candidate prolonged lives in trial", "summary": "BioNTech announced that its drug candidate, gotistobart, significantly extended overall survival in patients with squamous non-small cell lung cancer whose disease had progressed despite prior immunotherapy and chemotherapy. Results from the PRESERVE-003 Phase 3 clinical trial showed that gotistobart nearly doubled survival compared to standard-of-care chemotherapy. This marks a clinically meaningful benefit for a specific type of lung cancer.", "url": "https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-says-lung-cancer-drug-candidate-prolonged-lives-trial-2026-09-14", "source_link": "https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-says-lung-cancer-drug-candidate-prolonged-lives-trial-2026-09-14", "source_link_is_lookup": false, "source_name": "Reuters", "published_at": "2026-09-14T08:07:00", "published_display": "14 Sep 2026 08:07", "provider": "alphavantage", "providers": ["alphavantage", "archive"], "provider_symbol": "", "provider_symbols": ["BNTX", "BNTX.ARCHIVE"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["Reuters"], "source_kind": "editorial_wire", "story_key": "2997d129bd6fe02e978e87a22964dd87b5d8776d2fa9446f173443c844a3d57c", "target_scope": "BioNTech says lung cancer drug candidate prolonged lives in trial BioNTech announced that its drug candidate, gotistobart, significantly extended overall survival in patients with squamous non-small cell lung cancer whose disease had progressed despite prior immunotherapy and chemotherapy.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": 0.8197, "relevance_score": 1.0, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 1.2e-05, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.0, "age_days": 26.5, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": ["Life Sciences"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat", "summary": "Quick Read Moderna surges 8% while cancer-vaccine partner Merck slips 0.3% and peer BioNTech gains just 0.5%, pointing to a Moderna-specific momentum or short-squeeze event. XBI falls 0.1% and SPY rises less than 1%, eliminating both sector tailwinds and broad market strength as drivers of Moderna's rally. Already up 143% in a month on August's late-stage melanoma trial win, Moderna's latest jump has no new clinical, regulatory, or analyst trigger behind it. Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Merck didn't make the cut.", "url": "https://finance.yahoo.com/markets/stocks/articles/moderna-rallies-8-2026-melt-155630208.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/moderna-rallies-8-2026-melt-155630208.html", "source_link_is_lookup": false, "source_name": "24/7 Wall St.", "published_at": "2026-09-11T15:56:30+00:00", "published_display": "11 Sep 2026 15:56", "provider": "yfinance", "providers": ["archive", "eodhd", "yfinance"], "provider_symbol": "BNTX.US", "provider_symbols": ["BNTX", "BNTX.ARCHIVE", "BNTX.US", "GSPC.INDX", "MRK", "MRK.US", "MRNA", "MRNA.US", "SPY", "SPY.US", "XBI", "XBI.US", "^GSPC"], "target_provider_symbol": "BNTX", "cross_listing": false, "source_names": ["24/7 Wall St.", "finance.yahoo.com"], "source_kind": "publisher", "story_key": "c66d449dfb044387fe86e5a76d1ffb8ed8591b06fd262005e280bc2d520f321c", "target_scope": "BioNTech and Merck Stay Flat cancer-vaccine partner Merck slips 0.3% and peer BioNTech gains just 0.5%, pointing to a Moderna-specific momentum or short-squeeze event.", "durable_archive": false, "archive_provider": "", "sentiment_origin": "target_heuristic", "model_confidence": 0.51, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Positive financial language"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 2e-06, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 0.0, "age_days": 29.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 2, "topics": ["Biotech", "Cancer Vaccine", "Momentum", "Price Target"], "evidence_basis": "", "score_included": true, "direction_included": false}, {"title": "BioNTech (BNTX) Stock Stays Rich On Sales As Revenue Looks Weaker", "summary": "", "url": "https://news.google.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?oc=5", "source_link": "https://news.google.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?oc=5", "source_link_is_lookup": false, "source_name": "simplywall.st", "published_at": "2026-09-11T10:29:51+00:00", "published_display": "11 Sep 2026 10:29", "provider": "archive", "providers": ["archive", "google_news"], "provider_symbol": "", "provider_symbols": ["BNTX.ARCHIVE"], "target_provider_symbol": "BNTX.ARCHIVE", "cross_listing": false, "source_names": ["simplywall.st"], "source_kind": "publisher", "story_key": "a59f188fe56af94e2ba90f89ea613699e9a76aa0817421a0fc2dd4eb2e754872", "target_scope": "BioNTech (BNTX) Stock Stays Rich On Sales As Revenue Looks Weaker", "durable_archive": true, "archive_provider": "google_news", "sentiment_origin": "target_heuristic", "model_confidence": 0.46, "provider_directional_mass": null, "relevance_score": 0.78, "company_focus": 1.0, "company_focus_pct": 100, "company_focus_label": "Main company", "entity_mapped": true, "sentiment_conflict": 0.0, "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": [], "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.001607, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 1.7, "age_days": 29.4, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "headline_only", "score_included": true, "direction_included": false}], "industry": [], "sector": []}, "total_fetched": 53, "total_unique": 53, "total_relevant": 53, "pipeline_health": {"status": "healthy", "providers_attempted": 4, "providers_with_results": 4, "raw_articles": 168, "unique_stories": 97, "duplicates_removed": 71, "relevant_stories": 53, "matched_archive_stories": 72, "current_evidence": 16, "direct_evidence": 53, "archive_articles": 6, "durable_story_count": 53, "durable_evidence_used": true, "durable_collected_at": "2026-10-09T20:34:13.379488+00:00"}, "sentiment_summary": {"positive": 7, "negative": 9, "neutral": 37, "score": 50, "raw_score": 51, "total": 53, "evidence_count": 16, "effective_articles": 7.3, "information_mass": 0.33, "direct_story_count": 53, "directional_story_count": 16, "direct_source_count": 9, "industry_story_count": 0, "sector_story_count": 0, "story_count": 53, "source_count": 9, "source_concentration": 0.1915, "direct_share": 97, "dispersion": 15, "confidence": 25, "evidence_status": "provisional", "score_version": "evidence-v11", "window_days": 30, "weighting_method": "event-aware exponential freshness decay", "newest_article_at": "2026-10-09T15:48:54+00:00", "label": "Early balanced news score", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 78, "events": [{"event": "general", "label": "Market update", "weight": 17.55, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 7.84, "count": 12}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 3.22, "count": 5}, {"event": "analyst", "label": "Analyst action", "weight": 3.22, "count": 5}, {"event": "guidance", "label": "Guidance", "weight": 1.8, "count": 3}], "positive_events": 7, "negative_events": 9, "pipeline": {"status": "healthy", "providers_attempted": 4, "providers_with_results": 4, "raw_articles": 168, "unique_stories": 97, "duplicates_removed": 71, "relevant_stories": 53, "matched_archive_stories": 72, "current_evidence": 16, "direct_evidence": 53, "archive_articles": 6, "durable_story_count": 53, "durable_evidence_used": true, "durable_collected_at": "2026-10-09T20:34:13.379488+00:00"}}, "market_context": {"has_market_context": true, "latest_close": 96.96, "latest_week": "2026-10-09", "one_week_move": 0.1, "four_week_move": 0.2, "twelve_week_move": 6.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.307779, "market_dynamics_buy_signal": false, "relative_strength": -14.1373, "fair_value_gap": -3.5, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 48.9906, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.1% over one week, +0.2% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Early company-news score", "tone": "neutral", "classification": "provisional", "summary": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.", "confidence": 25, "badges": ["Provisional evidence"], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 7}, {"label": "24/7 Wall St.", "count": 6}, {"label": "AD HOC NEWS", "count": 5}, {"label": "Simply Wall St.", "count": 4}, {"label": "Yahoo! Finance Canada", "count": 3}, {"label": "The Motley Fool", "count": 3}, {"label": "Simply Wall Street", "count": 2}, {"label": "marketscreener.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 12}, {"label": "Analyst action", "count": 5}, {"label": "Regulatory and legal", "count": 5}, {"label": "Guidance", "count": 3}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Early balanced news score"}, {"label": "Evidence confidence", "value": "25/100", "tone": "neutral", "text": "7.3 effective stories after overlap and weighting."}, {"label": "Market reaction", "value": "Early company-news score", "tone": "neutral", "text": "Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "78/100 evidence concentration around this catalyst."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "97% of weighted evidence is company-specific."}, {"label": "Evidence agreement", "value": "15/100", "tone": "positive", "text": "lower dispersion means the independent stories agree more closely."}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.1% over one week, +0.2% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up"}], "updated_at": "2026-10-09T20:34:13.379488+00:00", "detail_intelligence": {"headline": "Early balanced news score", "summary": "53 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.", "status": "provisional", "metrics": [{"label": "News score", "value": 50, "display": "50", "tone": "neutral", "note": "Early balanced news score"}, {"label": "Confidence", "value": 25, "display": "25", "tone": "negative", "note": "thin evidence"}, {"label": "Company news", "value": 97, "display": "97%", "tone": "positive", "note": "53 company stories"}, {"label": "Story agreement", "value": 85, "display": "85", "tone": "positive", "note": "15/100 difference"}], "confidence_drivers": [{"label": "Amount of evidence", "value": 7, "note": "0.33 after freshness weighting"}, {"label": "Source breadth", "value": 100, "note": "9 independent publishers"}, {"label": "Company relevance", "value": 97, "note": "share tied directly to this company"}, {"label": "Freshness", "value": 40, "note": "recency-weighted evidence"}, {"label": "Agreement", "value": 85, "note": "how closely stories agree"}, {"label": "Publisher mix", "value": 81, "note": "less reliance on one publisher"}], "influence": {"events": [{"label": "Analyst action", "positive": 0.09282000000000001, "negative": 0.035186999999999996, "count": 4, "positive_share": 28.1, "positive_width": 39.52, "negative_share": 10.7, "negative_width": 14.982}, {"label": "Market update", "positive": 2.9e-05, "negative": 0.117434, "count": 8, "positive_share": 0.0, "positive_width": 0.012, "negative_share": 35.6, "negative_width": 50.0}, {"label": "Earnings", "positive": 0.043492, "negative": 0.0, "count": 2, "positive_share": 13.2, "positive_width": 18.518, "negative_share": 0.0, "negative_width": 0.0}, {"label": "Guidance", "positive": 0.030742, "negative": 0.0, "count": 1, "positive_share": 9.3, "positive_width": 13.089, "negative_share": 0.0, "negative_width": 0.0}, {"label": "Regulatory and legal", "positive": 0.010519, "negative": 0.0, "count": 1, "positive_share": 3.2, "positive_width": 4.479, "negative_share": 0.0, "negative_width": 0.0}], "sources": [{"label": "marketscreener.com", "weight": 0.087554, "count": 1, "share": 26.5}, {"label": "Stock Titan", "weight": 0.081703, "count": 6, "share": 24.7}, {"label": "AD HOC NEWS", "weight": 0.06592899999999999, "count": 3, "share": 20.0}, {"label": "www.marketscreener.com", "weight": 0.035731, "count": 1, "share": 10.8}, {"label": "The Motley Fool", "weight": 0.028299, "count": 1, "share": 8.6}, {"label": "Remaining publishers", "weight": 0.031007, "count": 4, "share": 9.4}], "directional_count": 16, "retained_count": 53, "source_count": 9, "top_share": 26.5, "axis_max": 35.6}, "freshness": 40, "source_independence": 81, "timeline": [{"date": "2026-09-11", "label": "11 Sep", "count": 2, "score": 50, "tone": "neutral", "x": 42.0, "y": 135.0, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-09-12", "label": "12 Sep", "count": 0, "score": null, "tone": "neutral", "x": 73.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-13", "label": "13 Sep", "count": 0, "score": null, "tone": "neutral", "x": 105.2, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-14", "label": "14 Sep", "count": 5, "score": 50, "tone": "neutral", "x": 136.8, "y": 135.0, "volume_height": 43.3, "volume_y": 222.7}, {"date": "2026-09-15", "label": "15 Sep", "count": 2, "score": 50, "tone": "neutral", "x": 168.3, "y": 135.0, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-09-16", "label": "16 Sep", "count": 2, "score": 56, "tone": "neutral", "x": 199.9, "y": 124.1, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-09-17", "label": "17 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 231.5, "y": 135.0, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-09-18", "label": "18 Sep", "count": 0, "score": null, "tone": "neutral", "x": 263.1, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-19", "label": "19 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 294.7, "y": 135.0, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-09-20", "label": "20 Sep", "count": 0, "score": null, "tone": "neutral", "x": 326.3, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-21", "label": "21 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 357.9, "y": 135.0, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-09-22", "label": "22 Sep", "count": 5, "score": 55, "tone": "neutral", "x": 389.4, "y": 125.9, "volume_height": 43.3, "volume_y": 222.7}, {"date": "2026-09-23", "label": "23 Sep", "count": 0, "score": null, "tone": "neutral", "x": 421.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-24", "label": "24 Sep", "count": 4, "score": 58, "tone": "positive", "x": 452.6, "y": 120.4, "volume_height": 34.7, "volume_y": 231.3}, {"date": "2026-09-25", "label": "25 Sep", "count": 2, "score": 50, "tone": "neutral", "x": 484.2, "y": 135.0, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-09-26", "label": "26 Sep", "count": 0, "score": null, "tone": "neutral", "x": 515.8, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-27", "label": "27 Sep", "count": 1, "score": 50, "tone": "neutral", "x": 547.4, "y": 135.0, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-09-28", "label": "28 Sep", "count": 6, "score": 52, "tone": "neutral", "x": 579.0, "y": 131.4, "volume_height": 52.0, "volume_y": 214.0}, {"date": "2026-09-29", "label": "29 Sep", "count": 0, "score": null, "tone": "neutral", "x": 610.6, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-09-30", "label": "30 Sep", "count": 5, "score": 41, "tone": "negative", "x": 642.1, "y": 151.4, "volume_height": 43.3, "volume_y": 222.7}, {"date": "2026-10-01", "label": "01 Oct", "count": 2, "score": 50, "tone": "neutral", "x": 673.7, "y": 135.0, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-10-02", "label": "02 Oct", "count": 1, "score": 40, "tone": "negative", "x": 705.3, "y": 153.2, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-10-03", "label": "03 Oct", "count": 2, "score": 50, "tone": "neutral", "x": 736.9, "y": 135.0, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-10-04", "label": "04 Oct", "count": 0, "score": null, "tone": "neutral", "x": 768.5, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}, {"date": "2026-10-05", "label": "05 Oct", "count": 3, "score": 48, "tone": "neutral", "x": 800.1, "y": 138.6, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-10-06", "label": "06 Oct", "count": 1, "score": 40, "tone": "negative", "x": 831.7, "y": 153.2, "volume_height": 8.7, "volume_y": 257.3}, {"date": "2026-10-07", "label": "07 Oct", "count": 3, "score": 56, "tone": "neutral", "x": 863.2, "y": 124.1, "volume_height": 26.0, "volume_y": 240.0}, {"date": "2026-10-08", "label": "08 Oct", "count": 2, "score": 50, "tone": "neutral", "x": 894.8, "y": 135.0, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-10-09", "label": "09 Oct", "count": 2, "score": 50, "tone": "neutral", "x": 926.4, "y": 135.0, "volume_height": 17.3, "volume_y": 248.7}, {"date": "2026-10-10", "label": "10 Oct", "count": 0, "score": null, "tone": "neutral", "x": 958.0, "y": 135.0, "volume_height": 0.0, "volume_y": 266.0}], "timeline_points": "42.0,135.0 136.8,135.0 168.3,135.0 199.9,124.1 231.5,135.0 294.7,135.0 357.9,135.0 389.4,125.9 452.6,120.4 484.2,135.0 547.4,135.0 579.0,131.4 642.1,151.4 673.7,135.0 705.3,153.2 736.9,135.0 800.1,138.6 831.7,153.2 863.2,124.1 894.8,135.0 926.4,135.0", "timeline_path": "M42.0,135.0 M136.8,135.0 L168.3,135.0 L199.9,124.1 L231.5,135.0 M294.7,135.0 M357.9,135.0 L389.4,125.9 M452.6,120.4 L484.2,135.0 M547.4,135.0 L579.0,131.4 M642.1,151.4 L673.7,135.0 L705.3,153.2 L736.9,135.0 M800.1,138.6 L831.7,153.2 L863.2,124.1 L894.8,135.0 L926.4,135.0", "timeline_has_signal": true, "timeline_start": "11 Sep", "timeline_mid": "26 Sep", "timeline_end": "10 Oct", "momentum": {"label": "Tentative cooling", "tone": "neutral", "recent_score": 48, "prior_score": 56, "delta": -8, "recent_count": 6, "prior_count": 5, "volume_delta": 1, "reliable": false, "reliability_note": "Thin comparison; direction is not yet confirmed"}, "early_change": {"label": "No new story in 24 hours", "tone": "neutral", "latest_score": null, "baseline_score": 51, "delta": null, "latest_count": 0, "baseline_count": 11, "confirmed": false, "note": "A comparison needs current and earlier-week company news"}, "freshness_buckets": [{"label": "Last 24 hours", "count": 0, "share": 0}, {"label": "1 to 3 days", "count": 6, "share": 11}, {"label": "4 to 7 days", "count": 5, "share": 9}, {"label": "8 to 14 days", "count": 17, "share": 32}, {"label": "15 to 21 days", "count": 12, "share": 23}, {"label": "22 to 30 days", "count": 13, "share": 25}], "source_profile": [{"label": "Stock Titan", "count": 7, "share": 13, "score": 41, "tone": "negative"}, {"label": "24/7 Wall St.", "count": 6, "share": 11, "score": 50, "tone": "neutral"}, {"label": "AD HOC NEWS", "count": 5, "share": 9, "score": 45, "tone": "neutral"}, {"label": "Simply Wall St.", "count": 4, "share": 8, "score": 49, "tone": "neutral"}, {"label": "The Motley Fool", "count": 3, "share": 6, "score": 51, "tone": "neutral"}, {"label": "Yahoo! Finance Canada", "count": 3, "share": 6, "score": 50, "tone": "neutral"}, {"label": "The Globe and Mail", "count": 2, "share": 4, "score": 71, "tone": "positive"}], "event_profile": [{"label": "Market update", "count": 28, "share": 53, "score": 45, "tone": "neutral"}, {"label": "Earnings", "count": 12, "share": 23, "score": 51, "tone": "neutral"}, {"label": "Analyst action", "count": 5, "share": 9, "score": 57, "tone": "neutral"}, {"label": "Regulatory and legal", "count": 5, "share": 9, "score": 51, "tone": "neutral"}, {"label": "Guidance", "count": 3, "share": 6, "score": 52, "tone": "neutral"}], "topics": [{"label": "Life Sciences", "count": 33, "share": 62}, {"label": "Financial Markets", "count": 24, "share": 45}, {"label": "Earnings", "count": 20, "share": 38}, {"label": "Biotech", "count": 11, "share": 21}, {"label": "Clinical Trials", "count": 8, "share": 15}, {"label": "Oncology", "count": 7, "share": 13}, {"label": "Pharma", "count": 5, "share": 9}, {"label": "Finance", "count": 5, "share": 9}, {"label": "Lung Cancer", "count": 3, "share": 6}, {"label": "Valuation", "count": 2, "share": 4}], "supporting": [{"label": "Direct evidence", "text": "53 current stories are mapped specifically to BNTX."}, {"label": "Source breadth", "text": "The score uses 9 publishers rather than depending on one outlet."}], "tempering": [{"label": "Too little evidence", "text": "The stories agree, but freshness-weighted evidence is only 0.330."}, {"label": "Confidence", "text": "Confidence is 25/100, below the threshold for a firm score."}], "supporting_heading": "What supports the score", "tempering_heading": "What limits the score", "latest_observation": {"title": "Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/moderna-climbs-5-nasdaq-100-154854096.html", "source_link": "https://finance.yahoo.com/markets/stocks/articles/moderna-climbs-5-nasdaq-100-154854096.html", "source_link_is_lookup": false, "source_name": "24/7 Wall St.", "published_at": "2026-10-09T15:48:54+00:00", "published_display": "09 Oct 2026 15:48", "source_kind": "publisher", "company_focus": 0.78, "company_focus_pct": 78, "company_focus_label": "Shared story", "sentiment": "neutral", "sentiment_pct": 50, "tone_signals": ["Large positive market reaction"], "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage", "is_stale": false, "evidence_weight": 0.029948, "evidence_share": 0.0, "evidence_share_display": "0", "freshness_pct": 66.5, "age_days": 1.2, "influence_label": "None", "evidence_strength": 0, "duplicate_count": 1, "topics": [], "evidence_basis": "", "score_included": true, "direction_included": false}, "article_count": 53, "updated_at": "2026-10-09T20:34:13.379488+00:00"}, "price_sentiment_path": {"available": true, "price_points": [{"x": 42.0, "y": 126.9, "label": "17 Apr 2026", "close": 102.92, "index": 100.0}, {"x": 78.4, "y": 113.7, "label": "24 Apr 2026", "close": 105.46, "index": 102.5}, {"x": 114.9, "y": 154.9, "label": "01 May 2026", "close": 97.54, "index": 94.8}, {"x": 151.3, "y": 172.7, "label": "08 May 2026", "close": 94.125, "index": 91.5}, {"x": 187.7, "y": 196.5, "label": "15 May 2026", "close": 89.55, "index": 87.0}, {"x": 224.2, "y": 183.0, "label": "22 May 2026", "close": 92.14, "index": 89.5}, {"x": 260.6, "y": 163.2, "label": "29 May 2026", "close": 95.95, "index": 93.2}, {"x": 297.0, "y": 204.2, "label": "05 Jun 2026", "close": 88.08, "index": 85.6}, {"x": 333.5, "y": 191.4, "label": "12 Jun 2026", "close": 90.54, "index": 88.0}, {"x": 369.9, "y": 189.6, "label": "19 Jun 2026", "close": 90.89, "index": 88.3}, {"x": 406.3, "y": 187.8, "label": "26 Jun 2026", "close": 91.22, "index": 88.6}, {"x": 442.8, "y": 154.9, "label": "03 Jul 2026", "close": 97.545, "index": 94.8}, {"x": 479.2, "y": 186.4, "label": "10 Jul 2026", "close": 91.49, "index": 88.9}, {"x": 515.6, "y": 186.5, "label": "17 Jul 2026", "close": 91.48, "index": 88.9}, {"x": 552.0, "y": 197.7, "label": "24 Jul 2026", "close": 89.33, "index": 86.8}, {"x": 588.5, "y": 191.2, "label": "31 Jul 2026", "close": 90.58, "index": 88.0}, {"x": 624.9, "y": 175.1, "label": "07 Aug 2026", "close": 93.67, "index": 91.0}, {"x": 661.3, "y": 178.1, "label": "14 Aug 2026", "close": 93.09, "index": 90.4}, {"x": 697.8, "y": 55.8, "label": "21 Aug 2026", "close": 116.57, "index": 113.3}, {"x": 734.2, "y": 131.3, "label": "28 Aug 2026", "close": 102.075, "index": 99.2}, {"x": 770.6, "y": 122.5, "label": "04 Sep 2026", "close": 103.76, "index": 100.8}, {"x": 807.1, "y": 159.1, "label": "11 Sep 2026", "close": 96.73, "index": 94.0}, {"x": 843.5, "y": 162.6, "label": "18 Sep 2026", "close": 96.06, "index": 93.3}, {"x": 879.9, "y": 149.8, "label": "25 Sep 2026", "close": 98.52, "index": 95.7}, {"x": 916.4, "y": 158.3, "label": "02 Oct 2026", "close": 96.9, "index": 94.2}, {"x": 952.8, "y": 157.9, "label": "09 Oct 2026", "close": 96.96, "index": 94.2}], "sentiment_points": [{"at": "2026-06-26T23:59:59.999Z", "date": "2026-06-26", "label": "26 Jun 2026", "score": 50, "tone": "neutral", "raw_score": 50, "confidence": 0, "stories": 4, "close": 91.22, "price_change": 0.4, "x": 411.5, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-07-03T23:59:59.999Z", "date": "2026-07-03", "label": "03 Jul 2026", "score": 49, "tone": "neutral", "raw_score": 43, "confidence": 27, "stories": 8, "close": 97.545, "price_change": 6.9, "x": 448.0, "y": 131.8, "show_label": false, "label_y": 121.80000000000001}, {"at": "2026-07-10T23:59:59.999Z", "date": "2026-07-10", "label": "10 Jul 2026", "score": 50, "tone": "neutral", "raw_score": 46, "confidence": 26, "stories": 13, "close": 91.49, "price_change": -6.2, "x": 484.4, "y": 130.0, "show_label": false, "label_y": 120.0}, {"at": "2026-07-17T23:59:59.999Z", "date": "2026-07-17", "label": "17 Jul 2026", "score": 51, "tone": "neutral", "raw_score": 59, "confidence": 20, "stories": 17, "close": 91.48, "price_change": -0.0, "x": 520.8, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-07-24T23:59:59.999Z", "date": "2026-07-24", "label": "24 Jul 2026", "score": 49, "tone": "neutral", "raw_score": 45, "confidence": 27, "stories": 26, "close": 89.33, "price_change": -2.4, "x": 557.2, "y": 131.8, "show_label": false, "label_y": 121.80000000000001}, {"at": "2026-07-31T23:59:59.999Z", "date": "2026-07-31", "label": "31 Jul 2026", "score": 52, "tone": "neutral", "raw_score": 56, "confidence": 29, "stories": 37, "close": 90.58, "price_change": 1.4, "x": 593.7, "y": 126.3, "show_label": false, "label_y": 116.3}, {"at": "2026-08-07T23:59:59.999Z", "date": "2026-08-07", "label": "07 Aug 2026", "score": 40, "tone": "negative", "raw_score": 35, "confidence": 49, "stories": 60, "close": 93.67, "price_change": 3.4, "x": 630.1, "y": 148.4, "show_label": true, "label_y": 138.4}, {"at": "2026-08-14T23:59:59.999Z", "date": "2026-08-14", "label": "14 Aug 2026", "score": 44, "tone": "neutral", "raw_score": 40, "confidence": 42, "stories": 68, "close": 93.09, "price_change": -0.6, "x": 666.5, "y": 141.0, "show_label": false, "label_y": 131.0}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "label": "21 Aug 2026", "score": 52, "tone": "neutral", "raw_score": 53, "confidence": 48, "stories": 73, "close": 116.57, "price_change": 25.2, "x": 703.0, "y": 126.3, "show_label": false, "label_y": 116.3}, {"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "label": "28 Aug 2026", "score": 49, "tone": "neutral", "raw_score": 49, "confidence": 51, "stories": 74, "close": 102.075, "price_change": -12.4, "x": 739.4, "y": 131.8, "show_label": true, "label_y": 121.80000000000001}, {"at": "2026-09-04T23:59:59.999Z", "date": "2026-09-04", "label": "04 Sep 2026", "score": 49, "tone": "neutral", "raw_score": 48, "confidence": 35, "stories": 57, "close": 103.76, "price_change": 1.7, "x": 775.8, "y": 131.8, "show_label": false, "label_y": 121.80000000000001}, {"at": "2026-09-11T23:59:59.999Z", "date": "2026-09-11", "label": "11 Sep 2026", "score": 49, "tone": "neutral", "raw_score": 48, "confidence": 33, "stories": 51, "close": 96.73, "price_change": -6.8, "x": 812.3, "y": 131.8, "show_label": false, "label_y": 121.80000000000001}, {"at": "2026-09-18T23:59:59.999Z", "date": "2026-09-18", "label": "18 Sep 2026", "score": 51, "tone": "neutral", "raw_score": 52, "confidence": 28, "stories": 49, "close": 96.06, "price_change": -0.7, "x": 848.7, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-09-25T23:59:59.999Z", "date": "2026-09-25", "label": "25 Sep 2026", "score": 52, "tone": "neutral", "raw_score": 54, "confidence": 33, "stories": 49, "close": 98.52, "price_change": 2.6, "x": 885.1, "y": 126.3, "show_label": false, "label_y": 116.3}, {"at": "2026-10-02T23:59:59.999Z", "date": "2026-10-02", "label": "02 Oct 2026", "score": 47, "tone": "neutral", "raw_score": 42, "confidence": 34, "stories": 46, "close": 96.9, "price_change": -1.6, "x": 921.6, "y": 135.5, "show_label": false, "label_y": 125.5}, {"at": "2026-10-09T23:59:59.999Z", "date": "2026-10-09", "label": "09 Oct 2026", "score": 50, "tone": "neutral", "raw_score": 49, "confidence": 27, "stories": 53, "close": 96.96, "price_change": 0.1, "x": 958.0, "y": 130.0, "show_label": true, "label_y": 120.0}], "price_path": "42.0,126.9 78.4,113.7 114.9,154.9 151.3,172.7 187.7,196.5 224.2,183.0 260.6,163.2 297.0,204.2 333.5,191.4 369.9,189.6 406.3,187.8 442.8,154.9 479.2,186.4 515.6,186.5 552.0,197.7 588.5,191.2 624.9,175.1 661.3,178.1 697.8,55.8 734.2,131.3 770.6,122.5 807.1,159.1 843.5,162.6 879.9,149.8 916.4,158.3 952.8,157.9", "sentiment_path": "411.5,130.0 448.0,131.8 484.4,130.0 520.8,128.2 557.2,131.8 593.7,126.3 630.1,148.4 666.5,141.0 703.0,126.3 739.4,131.8 775.8,131.8 812.3,131.8 848.7,128.2 885.1,126.3 921.6,135.5 958.0,130.0", "score_version": "evidence-v11", "price_change": -5.8, "sentiment_change": 0, "recent_pairs": [{"at": "2026-10-09T23:59:59.999Z", "date": "2026-10-09", "label": "09 Oct 2026", "score": 50, "tone": "neutral", "raw_score": 49, "confidence": 27, "stories": 53, "close": 96.96, "price_change": 0.1, "x": 958.0, "y": 130.0, "show_label": true, "label_y": 120.0}, {"at": "2026-10-02T23:59:59.999Z", "date": "2026-10-02", "label": "02 Oct 2026", "score": 47, "tone": "neutral", "raw_score": 42, "confidence": 34, "stories": 46, "close": 96.9, "price_change": -1.6, "x": 921.6, "y": 135.5, "show_label": false, "label_y": 125.5}, {"at": "2026-09-25T23:59:59.999Z", "date": "2026-09-25", "label": "25 Sep 2026", "score": 52, "tone": "neutral", "raw_score": 54, "confidence": 33, "stories": 49, "close": 98.52, "price_change": 2.6, "x": 885.1, "y": 126.3, "show_label": false, "label_y": 116.3}, {"at": "2026-09-18T23:59:59.999Z", "date": "2026-09-18", "label": "18 Sep 2026", "score": 51, "tone": "neutral", "raw_score": 52, "confidence": 28, "stories": 49, "close": 96.06, "price_change": -0.7, "x": 848.7, "y": 128.2, "show_label": true, "label_y": 118.19999999999999}, {"at": "2026-09-11T23:59:59.999Z", "date": "2026-09-11", "label": "11 Sep 2026", "score": 49, "tone": "neutral", "raw_score": 48, "confidence": 33, "stories": 51, "close": 96.73, "price_change": -6.8, "x": 812.3, "y": 131.8, "show_label": false, "label_y": 121.80000000000001}, {"at": "2026-09-04T23:59:59.999Z", "date": "2026-09-04", "label": "04 Sep 2026", "score": 49, "tone": "neutral", "raw_score": 48, "confidence": 35, "stories": 57, "close": 103.76, "price_change": 1.7, "x": 775.8, "y": 131.8, "show_label": false, "label_y": 121.80000000000001}, {"at": "2026-08-28T23:59:59.999Z", "date": "2026-08-28", "label": "28 Aug 2026", "score": 49, "tone": "neutral", "raw_score": 49, "confidence": 51, "stories": 74, "close": 102.075, "price_change": -12.4, "x": 739.4, "y": 131.8, "show_label": true, "label_y": 121.80000000000001}, {"at": "2026-08-21T23:59:59.999Z", "date": "2026-08-21", "label": "21 Aug 2026", "score": 52, "tone": "neutral", "raw_score": 53, "confidence": 48, "stories": 73, "close": 116.57, "price_change": 25.2, "x": 703.0, "y": 126.3, "show_label": false, "label_y": 116.3}], "reconstructed": true, "latest_close": 96.96, "price_observations": 26, "sentiment_observations": 16, "sentiment_start_label": "26 Jun 2026", "sentiment_end_label": "09 Oct 2026", "sentiment_history_limited": false, "price_axis_high": 116.6, "price_axis_mid": 99.4, "price_axis_low": 82.3, "start_label": "17 Apr", "mid_label": "14 Jul", "end_label": "09 Oct", "live_score_version": "evidence-v11", "comparable_to_live": true}, "sentiment_history": [{"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 38, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "01 Aug 23:59", "short_label": "01 Aug", "collected_at": "2026-08-01T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 39, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "03 Aug 23:59", "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": 9, "article_change": 4, "tone": "neutral", "height": 4, "articles": 43, "confidence": 36, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "04 Aug 23:59", "short_label": "04 Aug", "collected_at": "2026-08-04T23:59:59.999999+00:00", "score": 40, "delta": -10, "score_change": -10, "score_change_display": "-10", "confidence_change": 18, "article_change": 10, "tone": "negative", "height": 20, "articles": 53, "confidence": 54, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 40, "delta": -10, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 3, "tone": "negative", "height": 20, "articles": 56, "confidence": 53, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 40, "delta": -10, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": 4, "tone": "negative", "height": 20, "articles": 60, "confidence": 49, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 40, "delta": -10, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "negative", "height": 20, "articles": 61, "confidence": 48, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 39, "delta": -11, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": -1, "tone": "negative", "height": 22, "articles": 60, "confidence": 48, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 41, "delta": -9, "score_change": 2, "score_change_display": "+2", "confidence_change": -1, "article_change": 2, "tone": "negative", "height": 18, "articles": 62, "confidence": 47, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 41, "delta": -9, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 2, "tone": "negative", "height": 18, "articles": 64, "confidence": 47, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 42, "delta": -8, "score_change": 1, "score_change_display": "+1", "confidence_change": -3, "article_change": 2, "tone": "negative", "height": 16, "articles": 66, "confidence": 44, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "13 Aug 23:59", "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score": 42, "delta": -8, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 0, "tone": "negative", "height": 16, "articles": 66, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "14 Aug 23:59", "short_label": "14 Aug", "collected_at": "2026-08-14T23:59:59.999999+00:00", "score": 44, "delta": -6, "score_change": 2, "score_change_display": "+2", "confidence_change": 1, "article_change": 2, "tone": "neutral", "height": 12, "articles": 68, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "16 Aug 23:59", "short_label": "16 Aug", "collected_at": "2026-08-16T23:59:59.999999+00:00", "score": 44, "delta": -6, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": -1, "tone": "neutral", "height": 12, "articles": 67, "confidence": 39, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "17 Aug 23:59", "short_label": "17 Aug", "collected_at": "2026-08-17T23:59:59.999999+00:00", "score": 44, "delta": -6, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 12, "articles": 67, "confidence": 37, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "19 Aug 23:59", "short_label": "19 Aug", "collected_at": "2026-08-19T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 5, "score_change_display": "+5", "confidence_change": 14, "article_change": 6, "tone": "neutral", "height": 4, "articles": 73, "confidence": 51, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "20 Aug 23:59", "short_label": "20 Aug", "collected_at": "2026-08-20T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 3, "score_change_display": "+3", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 73, "confidence": 51, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "22 Aug 23:59", "short_label": "22 Aug", "collected_at": "2026-08-22T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -7, "article_change": -1, "tone": "neutral", "height": 4, "articles": 72, "confidence": 44, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "23 Aug 23:59", "short_label": "23 Aug", "collected_at": "2026-08-23T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": -1, "tone": "neutral", "height": 4, "articles": 71, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "24 Aug 23:59", "short_label": "24 Aug", "collected_at": "2026-08-24T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -3, "score_change_display": "-3", "confidence_change": 4, "article_change": 4, "tone": "neutral", "height": 4, "articles": 75, "confidence": 45, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "25 Aug 23:59", "short_label": "25 Aug", "collected_at": "2026-08-25T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 2, "score_change_display": "+2", "confidence_change": -2, "article_change": -1, "tone": "neutral", "height": 4, "articles": 74, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "27 Aug 23:59", "short_label": "27 Aug", "collected_at": "2026-08-27T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 4, "score_change_display": "+4", "confidence_change": 3, "article_change": -3, "tone": "neutral", "height": 8, "articles": 71, "confidence": 46, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "28 Aug 23:59", "short_label": "28 Aug", "collected_at": "2026-08-28T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -5, "score_change_display": "-5", "confidence_change": 5, "article_change": 3, "tone": "neutral", "height": 4, "articles": 74, "confidence": 51, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "29 Aug 23:59", "short_label": "29 Aug", "collected_at": "2026-08-29T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": -1, "tone": "neutral", "height": 4, "articles": 73, "confidence": 47, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "31 Aug 23:59", "short_label": "31 Aug", "collected_at": "2026-08-31T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 1, "score_change_display": "+1", "confidence_change": -5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 74, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "01 Sep 23:59", "short_label": "01 Sep", "collected_at": "2026-09-01T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -2, "score_change_display": "-2", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 76, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "02 Sep 23:59", "short_label": "02 Sep", "collected_at": "2026-09-02T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": -6, "tone": "neutral", "height": 4, "articles": 70, "confidence": 39, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "05 Sep 23:59", "short_label": "05 Sep", "collected_at": "2026-09-05T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": -6, "article_change": -12, "tone": "neutral", "height": 4, "articles": 58, "confidence": 33, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "06 Sep 23:59", "short_label": "06 Sep", "collected_at": "2026-09-06T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -1, "score_change_display": "-1", "confidence_change": 2, "article_change": -4, "tone": "neutral", "height": 4, "articles": 54, "confidence": 35, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "08 Sep 23:59", "short_label": "08 Sep", "collected_at": "2026-09-08T23:59:59.999999+00:00", "score": 45, "delta": -5, "score_change": -3, "score_change_display": "-3", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 10, "articles": 56, "confidence": 37, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true}, {"label": "11 Sep 23:59", "short_label": "11 Sep", "collected_at": "2026-09-11T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 4, "score_change_display": "+4", "confidence_change": -4, "article_change": -5, "tone": "neutral", "height": 4, "articles": 51, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "14 Sep 23:59", "short_label": "14 Sep", "collected_at": "2026-09-14T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 2, "score_change_display": "+2", "confidence_change": -2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 53, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "15 Sep 23:59", "short_label": "15 Sep", "collected_at": "2026-09-15T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 54, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "16 Sep 23:59", "short_label": "16 Sep", "collected_at": "2026-09-16T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 55, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "17 Sep 23:59", "short_label": "17 Sep", "collected_at": "2026-09-17T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 56, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "19 Sep 23:59", "short_label": "19 Sep", "collected_at": "2026-09-19T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": -11, "tone": "neutral", "height": 4, "articles": 45, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "21 Sep 23:59", "short_label": "21 Sep", "collected_at": "2026-09-21T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 2, "score_change_display": "+2", "confidence_change": 1, "article_change": -1, "tone": "neutral", "height": 4, "articles": 44, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "22 Sep 23:59", "short_label": "22 Sep", "collected_at": "2026-09-22T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": 9, "article_change": 4, "tone": "neutral", "height": 4, "articles": 48, "confidence": 36, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "24 Sep 23:59", "short_label": "24 Sep", "collected_at": "2026-09-24T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": -1, "tone": "neutral", "height": 4, "articles": 47, "confidence": 37, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "25 Sep 23:59", "short_label": "25 Sep", "collected_at": "2026-09-25T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": 2, "tone": "neutral", "height": 4, "articles": 49, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "27 Sep 23:59", "short_label": "27 Sep", "collected_at": "2026-09-27T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -5, "article_change": -10, "tone": "neutral", "height": 4, "articles": 39, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "28 Sep 23:59", "short_label": "28 Sep", "collected_at": "2026-09-28T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": 5, "article_change": 5, "tone": "neutral", "height": 4, "articles": 44, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "30 Sep 23:59", "short_label": "30 Sep", "collected_at": "2026-09-30T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": -4, "score_change_display": "-4", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 6, "articles": 46, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "01 Oct 23:59", "short_label": "01 Oct", "collected_at": "2026-10-01T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 6, "articles": 46, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "02 Oct 23:59", "short_label": "02 Oct", "collected_at": "2026-10-02T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 6, "articles": 46, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "03 Oct 23:59", "short_label": "03 Oct", "collected_at": "2026-10-03T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 2, "tone": "neutral", "height": 6, "articles": 48, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "05 Oct 23:59", "short_label": "05 Oct", "collected_at": "2026-10-05T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 2, "score_change_display": "+2", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 50, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "06 Oct 23:59", "short_label": "06 Oct", "collected_at": "2026-10-06T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 50, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "07 Oct 23:59", "short_label": "07 Oct", "collected_at": "2026-10-07T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 2, "score_change_display": "+2", "confidence_change": 3, "article_change": 3, "tone": "neutral", "height": 4, "articles": 53, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "08 Oct 23:59", "short_label": "08 Oct", "collected_at": "2026-10-08T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": -2, "tone": "neutral", "height": 4, "articles": 51, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "09 Oct 23:59", "short_label": "09 Oct", "collected_at": "2026-10-09T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 2, "tone": "neutral", "height": 4, "articles": 53, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "10 Oct 20:01", "short_label": "10 Oct", "collected_at": "2026-10-10T20:01:03.897211+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 53, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}], "sentiment_history_insight": {"available": true, "series_version": "evidence-v11", "live_version": "evidence-v11", "comparable_to_live": true, "reconstructed": true, "observations": 52, "span_label": "72 days", "first_score": 52, "latest_score": 50, "net_change": -2, "net_change_display": "-2", "direction": "Broadly stable", "high_score": 54, "low_score": 39, "latest_confidence": 25, "confidence_change": -7, "latest_articles": 53, "article_change": 15, "latest_label": "10 Oct 20:01", "latest_evidence_label": "Provisional", "chart_rows": [{"label": "30 Jul 23:59", "short_label": "30 Jul", "collected_at": "2026-07-30T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": null, "score_change_display": "Start", "confidence_change": null, "article_change": null, "tone": "neutral", "height": 4, "articles": 38, "confidence": 32, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 42.0, "y": 131.4}, {"label": "01 Aug 23:59", "short_label": "01 Aug", "collected_at": "2026-08-01T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 39, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 60.0, "y": 133.2}, {"label": "03 Aug 23:59", "short_label": "03 Aug", "collected_at": "2026-08-03T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": 9, "article_change": 4, "tone": "neutral", "height": 4, "articles": 43, "confidence": 36, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 77.9, "y": 135.0}, {"label": "04 Aug 23:59", "short_label": "04 Aug", "collected_at": "2026-08-04T23:59:59.999999+00:00", "score": 40, "delta": -10, "score_change": -10, "score_change_display": "-10", "confidence_change": 18, "article_change": 10, "tone": "negative", "height": 20, "articles": 53, "confidence": 54, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 95.9, "y": 153.2}, {"label": "05 Aug 23:59", "short_label": "05 Aug", "collected_at": "2026-08-05T23:59:59.999999+00:00", "score": 40, "delta": -10, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 3, "tone": "negative", "height": 20, "articles": 56, "confidence": 53, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 113.8, "y": 153.2}, {"label": "07 Aug 23:59", "short_label": "07 Aug", "collected_at": "2026-08-07T23:59:59.999999+00:00", "score": 40, "delta": -10, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": 4, "tone": "negative", "height": 20, "articles": 60, "confidence": 49, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 131.8, "y": 153.2}, {"label": "08 Aug 23:59", "short_label": "08 Aug", "collected_at": "2026-08-08T23:59:59.999999+00:00", "score": 40, "delta": -10, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 1, "tone": "negative", "height": 20, "articles": 61, "confidence": 48, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 149.8, "y": 153.2}, {"label": "09 Aug 23:59", "short_label": "09 Aug", "collected_at": "2026-08-09T23:59:59.999999+00:00", "score": 39, "delta": -11, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": -1, "tone": "negative", "height": 22, "articles": 60, "confidence": 48, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 167.7, "y": 155.0}, {"label": "10 Aug 23:59", "short_label": "10 Aug", "collected_at": "2026-08-10T23:59:59.999999+00:00", "score": 41, "delta": -9, "score_change": 2, "score_change_display": "+2", "confidence_change": -1, "article_change": 2, "tone": "negative", "height": 18, "articles": 62, "confidence": 47, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 185.7, "y": 151.4}, {"label": "11 Aug 23:59", "short_label": "11 Aug", "collected_at": "2026-08-11T23:59:59.999999+00:00", "score": 41, "delta": -9, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 2, "tone": "negative", "height": 18, "articles": 64, "confidence": 47, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 203.6, "y": 151.4}, {"label": "12 Aug 23:59", "short_label": "12 Aug", "collected_at": "2026-08-12T23:59:59.999999+00:00", "score": 42, "delta": -8, "score_change": 1, "score_change_display": "+1", "confidence_change": -3, "article_change": 2, "tone": "negative", "height": 16, "articles": 66, "confidence": 44, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 221.6, "y": 149.6}, {"label": "13 Aug 23:59", "short_label": "13 Aug", "collected_at": "2026-08-13T23:59:59.999999+00:00", "score": 42, "delta": -8, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 0, "tone": "negative", "height": 16, "articles": 66, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 239.6, "y": 149.6}, {"label": "14 Aug 23:59", "short_label": "14 Aug", "collected_at": "2026-08-14T23:59:59.999999+00:00", "score": 44, "delta": -6, "score_change": 2, "score_change_display": "+2", "confidence_change": 1, "article_change": 2, "tone": "neutral", "height": 12, "articles": 68, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 257.5, "y": 145.9}, {"label": "16 Aug 23:59", "short_label": "16 Aug", "collected_at": "2026-08-16T23:59:59.999999+00:00", "score": 44, "delta": -6, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": -1, "tone": "neutral", "height": 12, "articles": 67, "confidence": 39, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 275.5, "y": 145.9}, {"label": "17 Aug 23:59", "short_label": "17 Aug", "collected_at": "2026-08-17T23:59:59.999999+00:00", "score": 44, "delta": -6, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 12, "articles": 67, "confidence": 37, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 293.5, "y": 145.9}, {"label": "19 Aug 23:59", "short_label": "19 Aug", "collected_at": "2026-08-19T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 5, "score_change_display": "+5", "confidence_change": 14, "article_change": 6, "tone": "neutral", "height": 4, "articles": 73, "confidence": 51, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 311.4, "y": 136.8}, {"label": "20 Aug 23:59", "short_label": "20 Aug", "collected_at": "2026-08-20T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 3, "score_change_display": "+3", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 73, "confidence": 51, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 329.4, "y": 131.4}, {"label": "22 Aug 23:59", "short_label": "22 Aug", "collected_at": "2026-08-22T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -7, "article_change": -1, "tone": "neutral", "height": 4, "articles": 72, "confidence": 44, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 347.3, "y": 131.4}, {"label": "23 Aug 23:59", "short_label": "23 Aug", "collected_at": "2026-08-23T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -3, "article_change": -1, "tone": "neutral", "height": 4, "articles": 71, "confidence": 41, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 365.3, "y": 133.2}, {"label": "24 Aug 23:59", "short_label": "24 Aug", "collected_at": "2026-08-24T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -3, "score_change_display": "-3", "confidence_change": 4, "article_change": 4, "tone": "neutral", "height": 4, "articles": 75, "confidence": 45, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 383.3, "y": 138.6}, {"label": "25 Aug 23:59", "short_label": "25 Aug", "collected_at": "2026-08-25T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 2, "score_change_display": "+2", "confidence_change": -2, "article_change": -1, "tone": "neutral", "height": 4, "articles": 74, "confidence": 43, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 401.2, "y": 135.0}, {"label": "27 Aug 23:59", "short_label": "27 Aug", "collected_at": "2026-08-27T23:59:59.999999+00:00", "score": 54, "delta": 4, "score_change": 4, "score_change_display": "+4", "confidence_change": 3, "article_change": -3, "tone": "neutral", "height": 8, "articles": 71, "confidence": 46, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 419.2, "y": 127.7}, {"label": "28 Aug 23:59", "short_label": "28 Aug", "collected_at": "2026-08-28T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": -5, "score_change_display": "-5", "confidence_change": 5, "article_change": 3, "tone": "neutral", "height": 4, "articles": 74, "confidence": 51, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 437.1, "y": 136.8}, {"label": "29 Aug 23:59", "short_label": "29 Aug", "collected_at": "2026-08-29T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": -1, "tone": "neutral", "height": 4, "articles": 73, "confidence": 47, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 455.1, "y": 136.8}, {"label": "31 Aug 23:59", "short_label": "31 Aug", "collected_at": "2026-08-31T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 1, "score_change_display": "+1", "confidence_change": -5, "article_change": 1, "tone": "neutral", "height": 4, "articles": 74, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 473.1, "y": 135.0}, {"label": "01 Sep 23:59", "short_label": "01 Sep", "collected_at": "2026-09-01T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -2, "score_change_display": "-2", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 76, "confidence": 42, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 491.0, "y": 138.6}, {"label": "02 Sep 23:59", "short_label": "02 Sep", "collected_at": "2026-09-02T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": -6, "tone": "neutral", "height": 4, "articles": 70, "confidence": 39, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 509.0, "y": 138.6}, {"label": "05 Sep 23:59", "short_label": "05 Sep", "collected_at": "2026-09-05T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 1, "score_change_display": "+1", "confidence_change": -6, "article_change": -12, "tone": "neutral", "height": 4, "articles": 58, "confidence": 33, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 526.9, "y": 136.8}, {"label": "06 Sep 23:59", "short_label": "06 Sep", "collected_at": "2026-09-06T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -1, "score_change_display": "-1", "confidence_change": 2, "article_change": -4, "tone": "neutral", "height": 4, "articles": 54, "confidence": 35, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 544.9, "y": 138.6}, {"label": "08 Sep 23:59", "short_label": "08 Sep", "collected_at": "2026-09-08T23:59:59.999999+00:00", "score": 45, "delta": -5, "score_change": -3, "score_change_display": "-3", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 10, "articles": 56, "confidence": 37, "evidence_status": "measured", "evidence_label": "Measured", "score_version": "evidence-v11", "reconstructed": true, "x": 562.9, "y": 144.1}, {"label": "11 Sep 23:59", "short_label": "11 Sep", "collected_at": "2026-09-11T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 4, "score_change_display": "+4", "confidence_change": -4, "article_change": -5, "tone": "neutral", "height": 4, "articles": 51, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 580.8, "y": 136.8}, {"label": "14 Sep 23:59", "short_label": "14 Sep", "collected_at": "2026-09-14T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 2, "score_change_display": "+2", "confidence_change": -2, "article_change": 2, "tone": "neutral", "height": 4, "articles": 53, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 598.8, "y": 133.2}, {"label": "15 Sep 23:59", "short_label": "15 Sep", "collected_at": "2026-09-15T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 1, "tone": "neutral", "height": 4, "articles": 54, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 616.7, "y": 133.2}, {"label": "16 Sep 23:59", "short_label": "16 Sep", "collected_at": "2026-09-16T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": 2, "article_change": 1, "tone": "neutral", "height": 4, "articles": 55, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 634.7, "y": 133.2}, {"label": "17 Sep 23:59", "short_label": "17 Sep", "collected_at": "2026-09-17T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 1, "tone": "neutral", "height": 4, "articles": 56, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 652.7, "y": 133.2}, {"label": "19 Sep 23:59", "short_label": "19 Sep", "collected_at": "2026-09-19T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": -1, "score_change_display": "-1", "confidence_change": -4, "article_change": -11, "tone": "neutral", "height": 4, "articles": 45, "confidence": 26, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 670.6, "y": 135.0}, {"label": "21 Sep 23:59", "short_label": "21 Sep", "collected_at": "2026-09-21T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 2, "score_change_display": "+2", "confidence_change": 1, "article_change": -1, "tone": "neutral", "height": 4, "articles": 44, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 688.6, "y": 131.4}, {"label": "22 Sep 23:59", "short_label": "22 Sep", "collected_at": "2026-09-22T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": 9, "article_change": 4, "tone": "neutral", "height": 4, "articles": 48, "confidence": 36, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 706.5, "y": 131.4}, {"label": "24 Sep 23:59", "short_label": "24 Sep", "collected_at": "2026-09-24T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": 1, "article_change": -1, "tone": "neutral", "height": 4, "articles": 47, "confidence": 37, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 724.5, "y": 131.4}, {"label": "25 Sep 23:59", "short_label": "25 Sep", "collected_at": "2026-09-25T23:59:59.999999+00:00", "score": 52, "delta": 2, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": 2, "tone": "neutral", "height": 4, "articles": 49, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 742.5, "y": 131.4}, {"label": "27 Sep 23:59", "short_label": "27 Sep", "collected_at": "2026-09-27T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": -1, "score_change_display": "-1", "confidence_change": -5, "article_change": -10, "tone": "neutral", "height": 4, "articles": 39, "confidence": 28, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 760.4, "y": 133.2}, {"label": "28 Sep 23:59", "short_label": "28 Sep", "collected_at": "2026-09-28T23:59:59.999999+00:00", "score": 51, "delta": 1, "score_change": 0, "score_change_display": "+0", "confidence_change": 5, "article_change": 5, "tone": "neutral", "height": 4, "articles": 44, "confidence": 33, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 778.4, "y": 133.2}, {"label": "30 Sep 23:59", "short_label": "30 Sep", "collected_at": "2026-09-30T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": -4, "score_change_display": "-4", "confidence_change": 2, "article_change": 2, "tone": "neutral", "height": 6, "articles": 46, "confidence": 35, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 796.4, "y": 140.5}, {"label": "01 Oct 23:59", "short_label": "01 Oct", "collected_at": "2026-10-01T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 0, "score_change_display": "+0", "confidence_change": -1, "article_change": 0, "tone": "neutral", "height": 6, "articles": 46, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 814.3, "y": 140.5}, {"label": "02 Oct 23:59", "short_label": "02 Oct", "collected_at": "2026-10-02T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 6, "articles": 46, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 832.3, "y": 140.5}, {"label": "03 Oct 23:59", "short_label": "03 Oct", "collected_at": "2026-10-03T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 2, "tone": "neutral", "height": 6, "articles": 48, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 850.2, "y": 140.5}, {"label": "05 Oct 23:59", "short_label": "05 Oct", "collected_at": "2026-10-05T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 2, "score_change_display": "+2", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 50, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 868.2, "y": 136.8}, {"label": "06 Oct 23:59", "short_label": "06 Oct", "collected_at": "2026-10-06T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 50, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 886.2, "y": 138.6}, {"label": "07 Oct 23:59", "short_label": "07 Oct", "collected_at": "2026-10-07T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 2, "score_change_display": "+2", "confidence_change": 3, "article_change": 3, "tone": "neutral", "height": 4, "articles": 53, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 904.1, "y": 135.0}, {"label": "08 Oct 23:59", "short_label": "08 Oct", "collected_at": "2026-10-08T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": -2, "tone": "neutral", "height": 4, "articles": 51, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 922.1, "y": 135.0}, {"label": "09 Oct 23:59", "short_label": "09 Oct", "collected_at": "2026-10-09T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 2, "tone": "neutral", "height": 4, "articles": 53, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 940.0, "y": 135.0}, {"label": "10 Oct 20:01", "short_label": "10 Oct", "collected_at": "2026-10-10T20:01:03.897211+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 53, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true, "x": 958.0, "y": 135.0}], "chart_points": "42.0,131.4 60.0,133.2 77.9,135.0 95.9,153.2 113.8,153.2 131.8,153.2 149.8,153.2 167.7,155.0 185.7,151.4 203.6,151.4 221.6,149.6 239.6,149.6 257.5,145.9 275.5,145.9 293.5,145.9 311.4,136.8 329.4,131.4 347.3,131.4 365.3,133.2 383.3,138.6 401.2,135.0 419.2,127.7 437.1,136.8 455.1,136.8 473.1,135.0 491.0,138.6 509.0,138.6 526.9,136.8 544.9,138.6 562.9,144.1 580.8,136.8 598.8,133.2 616.7,133.2 634.7,133.2 652.7,133.2 670.6,135.0 688.6,131.4 706.5,131.4 724.5,131.4 742.5,131.4 760.4,133.2 778.4,133.2 796.4,140.5 814.3,140.5 832.3,140.5 850.2,140.5 868.2,136.8 886.2,138.6 904.1,135.0 922.1,135.0 940.0,135.0 958.0,135.0", "changes": [{"label": "10 Oct 20:01", "short_label": "10 Oct", "collected_at": "2026-10-10T20:01:03.897211+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -2, "article_change": 0, "tone": "neutral", "height": 4, "articles": 53, "confidence": 25, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "09 Oct 23:59", "short_label": "09 Oct", "collected_at": "2026-10-09T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 2, "tone": "neutral", "height": 4, "articles": 53, "confidence": 27, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "08 Oct 23:59", "short_label": "08 Oct", "collected_at": "2026-10-08T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 0, "score_change_display": "+0", "confidence_change": -4, "article_change": -2, "tone": "neutral", "height": 4, "articles": 51, "confidence": 30, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "07 Oct 23:59", "short_label": "07 Oct", "collected_at": "2026-10-07T23:59:59.999999+00:00", "score": 50, "delta": 0, "score_change": 2, "score_change_display": "+2", "confidence_change": 3, "article_change": 3, "tone": "neutral", "height": 4, "articles": 53, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "06 Oct 23:59", "short_label": "06 Oct", "collected_at": "2026-10-06T23:59:59.999999+00:00", "score": 48, "delta": -2, "score_change": -1, "score_change_display": "-1", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 4, "articles": 50, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "05 Oct 23:59", "short_label": "05 Oct", "collected_at": "2026-10-05T23:59:59.999999+00:00", "score": 49, "delta": -1, "score_change": 2, "score_change_display": "+2", "confidence_change": 0, "article_change": 2, "tone": "neutral", "height": 4, "articles": 50, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "03 Oct 23:59", "short_label": "03 Oct", "collected_at": "2026-10-03T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 0, "score_change_display": "+0", "confidence_change": -3, "article_change": 2, "tone": "neutral", "height": 6, "articles": 48, "confidence": 31, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}, {"label": "02 Oct 23:59", "short_label": "02 Oct", "collected_at": "2026-10-02T23:59:59.999999+00:00", "score": 47, "delta": -3, "score_change": 0, "score_change_display": "+0", "confidence_change": 0, "article_change": 0, "tone": "neutral", "height": 6, "articles": 46, "confidence": 34, "evidence_status": "provisional", "evidence_label": "Provisional", "score_version": "evidence-v11", "reconstructed": true}]}, "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}